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Abstract The IL-10 family of cytokines is comprised of
IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, and IFN-ks
(IL-28A, IL-28B, and IL-29). The IL-10 family members
bind to shared class II cytokine receptor chains that asso-
ciate in various combinations in heterodimeric complexes.
Upon interleukin/receptor complex formation, these pro-
teins switch on the Jak/STAT pathway and elicit
pleiotropic biological responses whose variety sharply
contrasts with their structural similarities. IL-10 family
members are involved in several human diseases and health
conditions and hence their structural analyses may provide
valuable information to design specific therapeutic strate-
gies. In this review, we describe the human interleukin-10
family of cytokines, focusing on their structures and
functions, with particular attention given to IL-22 and
IL-10. We report on the recently published structures of
IL-10 cytokine family members and their complexes with
cognate transmembrane and soluble receptors as well as on
interleukin physiology and physiopathology.
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Introduction
Immunomodulation is a primary physiological function of
interleukins such as interleukin-10 (IL-10), which was
originally described as a factor that inhibits IFN-c
production by T lymphocytes [1]. Ten years after the
original identification of IL-10, various genetic approa-
ches led to the cloning of a series genes coding for
IL-10-related factors that are now collectively described
as the IL-10 family, which comprises IL-10, IL-19, IL-20,
IL-22, IL-24, IL-26, and interferon-ks: IL-28A (IFN-k2),
IL-28B (IFN-k3), and IL-29 (IFN-k1). These cytokines
were grouped together based on sequence alignment,
structural homology, and binding to shared class II
cytokine receptor chains that activate the JAK/STAT
pathway [2–5]. IL-10 family members are helical proteins
formed by six or seven helices and connecting loops
[6–8]. Each IL-10 member can associate with the extra-
cellular portion of two transmembrane proteins from the
class II cytokine receptor, forming a heterodimeric
complex. There are six different receptor chains for
nine ligands, four with a long cytoplasmic tail (IL-10R1,
IL-20R1, IL-22R1, and IL-28R) and two with a short
cytoplasmic domain (IL-10R2 and IL-20R2), and each of
the members of the IL-10 family bind to either IL-10R2
or IL-20R2 associated with a long receptor chain [9–13].
Besides these transmembrane proteins, a soluble receptor
has also been described and designated IL-22 binding
protein (IL-22BP) because it binds and neutralizes IL-22
in vitro. The type I IFN-s and IFN-c also share some
structural characteristics with this family [14], but they
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do not share any of these receptor chains, and will not be
described in this review.
IL-10 family proteins are involved in a broad range of
biological processes that include antiviral activity, secre-
tion of antibacterial proteins, cell-growth stimulation, acute
phase response, wound healing, antitumoral activity, and
apoptosis induction. These important immunological
activities are implicated in several human diseases such as
psoriasis [15–17], rheumatoid arthritis [18–20], and
inflammatory lung and bowel diseases [21, 22]. In this
context, the study of IL-10 members, their interaction with
receptors, and elicited cell signaling cascade, are important
to understand the basis of both immunoregulation and
associated diseases, establishing strategies to modulate or
to control these health conditions and illnesses.
In this review, we discuss the human IL-10 family of
cytokines starting from a structural point of view. First,
we describe the relationships among the IL-10 members,
their amino acid sequence alignment, as well as the
similarities and clustering of these cytokines. Subse-
quently, we devote one section to every member of the
family, in which a brief biological introduction precedes
the structural considerations.
We also present the mechanism by which the IL-10
members signal throughout the target cell surfaces by
interacting with their cognate receptors. The IL-10 recep-
tors are introduced and the possible ternary complexes
formed by the interleukins and the different receptors are
discussed. Three-dimensional structures of the recently
published IL-10 and IL-22 complexes with their receptors
(IL-10:IL-10R1; IL-22:IL-22R1 and IL-22:IL-22BP) are
described in detail, and their interfaces and amino acid
residues involved in protein–protein interactions are ana-
lyzed. We also compare different IL-10 member binary
complexes, which shed light onto the molecular basis of
receptor selectivity and/or promiscuity.
Finally, we review important publications which use
molecular modeling tools and site direct mutagenesis
analysis to pinpoint the second receptor interfaces on the
surface of IL-10 and IL-22 binary complexes. Similar
analysis performed for the IL-10 members with unknown
binary complex structures is also presented.
The IL-10 members
Primary structures
The sequence alignment of IL-10 members (Fig. 1) shows
that these cytokines share 15–39% amino acid sequence
identity, except for the interferon-k cluster, which displays
less than 10% identity with the other IL-10 members and
shows a much higher amino acid conservation within the
cluster ([70%). IL-20 and IL-24 are very similar to IL-19,
with 39 and 30% of amino acid identity with IL-19,
respectively, thereby forming another cluster. IL-10 and
IL-26 share relatively high identity (24%) and are also
proposed to form a separate cluster within the IL-10 fam-
ily, whereas IL-22 seems to be relatively more closely
related to the IFN-ks than the other IL-10 family members
[23].
A common hydrophobic signal peptide, about 20 amino
acids in length, is found at the N-terminal region of all
IL-10 members. Another common feature of these cyto-
kines is a sequence signature K A/S X G/S E X D XX
(where X is a hydrophobic residue) identified in all non-
interferon IL-10 members (reviewed in [8]; Fig. 1a).
The cysteine residues are partially conserved and have a
somewhat complex distribution pattern (Table 1). All
members of the family possess at least one Cys residue at
the N-terminal portion and a highly conserved cysteine is
observed in the DE loop region (IL-24 being the only
exception). IL-10, IL-19, IL-20, and IL-26 all display an
additional Cys residue at the DE loop; however IL-19 and
IL-20 also contain one more cysteine (a total of three Cys
residues) located at the DE loop. The non-interferon
members also contain another highly conserved Cys resi-
due at the helix C. Notably, IL-22 is the unique non-
interferon IL-10 member that contains a Cys residue at the
helix F.
The IFN-k group displays quite a different distribution
pattern of cysteine residues. All three IFN-ks have highly
conserved cysteines at the AB loop, helix F, C-termini, and
N-termini regions. IFN-k2 and IFN-k3 also display an
additional cysteine at the C-termini of their helices F2,
promoting the formation of an additional S–S bond in the
C-terminal part of the protein (Fig. 1a; Table 1).
Three-dimensional structure considerations
The crystal structures of IL-10 [6, 7], IL-19 [24], IL-22 [8,
25], and, more recently, IFN-k3 [23] have been deter-
mined. Based on the information extracted from these 3D
structures, as well as sequence alignments and secondary
structure prediction, one can draw several conclusions
about IL-10 family members’ secondary, tertiary, and
quaternary organization.
IL-10 family members are helical cytokines formed by
six or seven helices and connecting loops. A four-helix
bundle, generally formed by helices A, C, D, and F,
comprises the protein core, which is a characteristic feature
of all these helical cytokines [13, 23, 24, 26]. Despite the
partially conserved cysteine positions among the members
of the IL-10 family, the organizations of the disulfide
networks are quite different, as revealed by the crystal
structures of IL-10, IL-19, IL-22, and IFN-k3. A
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characteristic helix F kink is observed in all known 3D
structures of IL-10 family members. This kink divides
helix F into two parts, generally designated helix F1 and
F2. As it will be discussed below, the kink exposes
important residues that contribute to the interaction sites
with the respective receptors [27, 28].
From the quaternary structure point of view, IL-10
family members can be found either as monomers [8, 23,
24] or intimately intertwined dimers [6, 13]. The prefer-
ence for dimer or monomer formation is most probably a
consequence of S–S interactions with the DE loop and/or
the length of this loop. In particular, disulfide interactions
in the beginning of helix E may influence the flexibility of
this helix. As a consequence of these interactions, helices
E and F could not fold back onto the same monomer [26]
and instead form a separated EF domain that is donated to
the homodimerization partner in the process of dimer
formation. IL-10, for example, forms an intertwined
dimer in which one compact domain is composed of
helices A–D and helices E0 and F0 from its intimate
dimeric counterpart [13] (Fig. 2a). A similar dimeric
conformation has been described for IFN-c [6, 13].
Alternatively, depending on the length and flexibility of
the DE loop [26] and/or the orientation promoted by
additional disulfide bridges [23], all the six to seven
helices can fold up as an individual monomer, as
Fig. 1 Alignment of the IL-10 family member amino acid sequences.
a Sequence alignment colored according to the ClustalW/Jalview
color code [169]. The potential cysteines involved in disulfides and
the non-interferon IL-10 member sequence signature are contoured by
solid and dashed lines, respectively. The secondary structures features
are shown as found in the IL-22 crystal structure (PDB ID 1M4R [8]).
The potential IL-22 [25, 56] and IL-19 [24] glycosylation sites are
contoured by double lines. b A phylogram tree extract from this
alignment. Alignment was performed using ClustalW [170]
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Fig. 2 IL-10 family members with known crystal structures. a The
intertwined IL-10 dimer (PDB ID 2ILK [7]). b The independent
monomers of IL-22 (PDB ID 1M4R [8]), IL-19 (PDB ID 2N1F [24]),
and IL-28B (IFN-k3; PDB ID 3HHC [23]). Helices are named and
the cysteine residues involved in disulfide linkages are shown as
sticks and numbered according Table 1. Figures were generated with
the PyMOL software (DeLano Scientific) [171]
Table 1 Cysteine residues and
observed disulfide interactions
found in amino acid sequences
and crystal structures of IL-10
family members
a Crystal structure numbering
b Full-length amino acid
sequence
IL-10 member Disulfide/cysteine position Connections
IL-10a 1: 12, 108 N-term to helix D
2: 62, 114 Helix C to DE loop [13]
IL-19a 1: 10, 103 Helix A/preA loop to helix D
2: 57, 109 Helix C to DE loop
3: 58–111 Helix C to DE loop [24]
IL-20b 33, 80, 81, 126, 132, 134 Probably identical to IL-19 [24]
IL-22b 1: 40, 132 N-term to DE loop
2: 89, 178 Helix C to helix F [8]
IL-24b 59, 106 Probably N-term to helix C [24]
IL-26b 32, 79, 102, 121, 124 Probably similar to IL-10 [138]
IFN-k2b 41, 73, 75, 140, 172, 192, 199 Probably identical to IFN-k3 [23]
IFN-k3a 1: 4, 103 N-term to helix D
2: 38, 136 AB loop to helix F1
3:155, 162 Helix F2 to C-term [23]
IFN-k1b 34, 68, 131, 164, 190 Probably similar to IFN-k3, with the
exception of interaction #3 [23]
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observed in IL-19, IL-22, and IFN-k3 crystal structures
(Fig. 2b).
Below, we will describe in detail each IL-10 family
member. We divided this section into two parts based on
their quaternary structures: the monomeric cytokines are
designated as ‘the IL-19 subfamily’ (IL-19, IL-20, IL-22,
IL-24, and INF-ks) and ‘the IL-10 family members that
form intertwined dimers’ which includes IL-10 and IL-26
descriptions. A brief introduction presenting the biological
aspects of each family member is given, followed by a
detailed structural description of the cytokines with the
known 3D structure: IL-10, IL-19, IL-22, and IFN-k3. We
will also briefly discuss the possible structural architectures
of the IL-10 members whose 3D structures are unknown, as
well as sequence alignments and secondary structure
predictions.
The IL-19 subfamily
The non-interferon IL-10 family members are IL-19, IL-20,
IL-22, and IL-24. From a structural point of view, these
cytokines compose the IL-19 sub-family, whose member’s
main feature is their quaternary assembly as individual
monomers [24]. Recently, the IFN-k group of cytokines was
also included in the IL-19 sub-family, after IFN-k3 crystal
structure determination [23] and based on the structural
comparison (reviewed in [29]). All these proteins are found
as individual monomers, and do not form intertwined dimers
characteristic for IL-10 and IL-26 [8, 13, 29].
IL-22
IL-22 was first identified as a gene induced by interleukin-9
(IL-9) in murine T lymphoma cells [30]. Because it
encodes a glycosylated protein that bears 22% identity to
interleukin-10 (IL-10) its original designation was IL-10-
related T-cell-derived inducible factor (IL-TIF). The
human IL-22 gene is located on chromosome 12q15, in the
vicinity of interferon-c (IFN-c) and interleukin-26 (IL-26)
genes, forming an interleukin gene cluster [31]. IL-22
genomic structure is composed of five introns and six
exons that are similar in size and organization when
compared to IL-10.
IL-22 expression was found to be induced by IL-9 in
thymic lymphomas, T helper cells, and mast cells, and also
upon ConA activation of freshly isolated splenocytes.
Similar induction was observed after lipopolysaccharide
injection in mice, and that was the first indication of IL-22
involvement in the inflammatory response in vivo [32]. Its
first biological activity described was the induction of acute
phase reactants such as serum amyloid A, a1-antichymo-
trypsin, and haptoglobin in hepatocytes [32] and in
pancreatic cell lines [33].
More recently, it was shown that IL-22 and IL-17 can be
coexpressed by Th17 cells [34, 35]. These cells correspond
to a separate lineage of effector CD4? T cells, defined on
the basis of their high IL-17 production [36]. The expres-
sion of both cytokines in these cells enhances cooperative
secretion of antimicrobial peptides involved in skin innate
immunity [34, 35], and initially pointed to a proinflam-
matory role of the interleukin.
The dual biological role of IL-22 As soon as it was found
that IL-22 mediates its activity on hepatocytes through
binding to the IL-22R1/IL-10R2 receptor complex,
screening for IL-22R1 receptor expression was conducted
to identify the potential biological targets of this cytokine.
IL-10R2 is expressed constitutively by almost every cell
type. IL-22R1 expression turned out to be more restricted
and was mostly found in cells from the skin, digestive, and
respiratory tracts. Interestingly, IL-22 stimulates the pro-
duction of b-defensin 2 and 3 in keratinocytes [37]. These
small cationic proteins kill bacteria and fungi, and are
normally expressed in skin and mucosal epithelia, acting as
an innate immunity barrier against microbial infections
[38, 39]. Besides inducing the expression of antimicrobial
genes, IL-22 also regulates cellular differentiation and
motility of keratinocytes, thereby exerting a spectrum of
activities that are beneficial during wound healing and
infectious processes, but that contribute to skin lesions of
patients with psoriasis disease [16, 35, 37, 40–42].
Whether these biological activities should be considered
as proinflammatory remains an open question. On the one
hand, in the context of psoriasis lesions, IL-22 definitely
plays a proinflammatory role. On the other hand, IL-22
exerts a protective effect in inflammatory and infectious
processes affecting the intestinal and respiratory mucosa,
both by inducing the production of anti-microbial proteins
and by promoting homeostasis of epithelial cells [43–47].
IL-22 also plays a protective role in an hepatitis model by
promoting hepatocyte survival [48, 49].
Altogether, these findings indicate that upon bacterial
infection in physiologically outer barriers, where IL-22R1
receptor is mostly expressed such as the skin and mucosal
epithelia, IL-22 secretion promotes a response aiming at
wound healing and pathogen killing [50]. In this context, a
TH17 lymphocyte response contributes to tissue homeo-
stasis, but other cell lineages might be involved in IL-22
production as well. Recently, three independent studies
described mucosal NKp46? cells as a subpopulation of
natural killer cells that secrete IL-22 in the intestinal
mucosa [51–53]. Moreover, NK-22 is another subset of
natural killer cells that when stimulated with IL-23 secretes
IL-22, IL-26, and leukemia inhibitory factor in mucosa-
associated lymphoid tissues such as tonsils and Peyer’s
patches (located in the lowest portion of the small intestine
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ileum) [54]. For both TH17, NK, or NK-like cells, IL-23
appears to be a major inducer of IL-22 production, sug-
gesting that IL-22 is a key mediator in IL-23-dependent
immune reactions in skin and mucosal epithelia by stimu-
lating innate antimicrobial responses as well as promoting
tissue repair.
IL-22 structures The crystal structures of human IL-22
were solved independently for IL-22 proteins expressed in
E. coli (ECIL-22, PDB ID 1M4R [8]) and D. melanogaster
(DMIL-22 PDB ID 1YKB [25]). The ECIL-22 and DMIL-22
show minimal structural divergences [25, 26].
The IL-22 monomer is composed of six helices named
A–F and a small N-terminal helix termed helix preA. IL-22
helices A–F are folded together forming a compact six-helix
bundle, of which helices A, C, D, and F form the charac-
teristic class II cytokines four-helix bundle. The N-terminal
portion of IL-22 (residues 44–47) acquires a 310-helix sec-
ondary structure (helix preA) [8, 25]. The preA structure is
oriented perpendicular to the IL-22 helix A, and is stabilized
by hydrogen bonds between residues Asp43–Ser45, Asp43–
Asn46, and Ser45–Gln49 [25]. Despite the preA kink, the
helix A is straight and continuous, as well as all the other
IL-22 helices, with the exception of helix F. IL-22 displays
the characteristic helix F bend found in all class II alpha-
helical cytokines [26, 55]. As a consequence, helix F can be
divided into two parts, helix F1 and helix F2. In IL-22 the
helix F bend occurs at the position of the residue Glu166,
exposing to solvent this and the neighboring residues
charged side chains (Figs. 1a, 2b).
The DMIL-22 carries several carbohydrates attached to
some of the predicted IL-22 glycosylation sites, which
provides additional information on the carbohydrate posi-
tions, compositions, and their importance to IL-22 structure
and putative interactions with IL-22 receptors [25]. Three
potential glycosylation sites (Asn-X-Ser/Thr, X = any
amino acid), which correspond to Asn54, Asn68, and
Asn97, map to IL-22 helix A, AB loop and helix C,
respectively (Fig. 1a). Mass spectroscopy analysis revealed
that hexasaccharides (two N-acetyl glucosamines, three
mannoses, and one fucose) are attached to the IL-22 pro-
tein expressed in D. melanogaster [56]. However, only
glycosylation at Asn54 and Asn97 position was observed in
the DMIL-22 crystal structure [25]. By analysis of the six
different IL-22 monomers packed into the DMIL-22 crystal
asymmetric unit, as well as their comparison to the ECIL-22
crystal structure, Xu et al. [25] pinpointed IL-22 regions
susceptible to conformational changes. These include the
helix preA, helix A, the AB loop, and helix D. In particular,
Gln49 and Pro50, located at the beginning of helix A, are
considered as a ‘flexible pivot point’, which allows the
preA and helix A to undergo rigid body conformational
motions. Notably, Pro50 is conserved in all IL-22
sequences from different organisms known to date [25, 26].
The rigid body conformational changes allow, for example,
reorientation of the Tyr51 side chain (helix A) as well as
the Tyr114–Glu117 main chains (helix D). These IL-22
structural adjustments are most probably important for the
binary and ternary complex formation, as will be discussed
further in this review.
In the ECIL-22 and DMIL-22 crystal structures the six
helices form a single IL-22 monomer. Asymmetric unit
cells of the ECIL-22 and DMIL-22 crystals contain two and
six IL-22 monomers, respectively. The absence of inter-
twined dimers, as observed in IL-10, and the monomer
contacts organization in IL-22 crystal structures supported
the idea that IL-22 is a monomer in solution [8, 25]. The
IL-22 monomer has two disulfide bonds (Fig. 2b; Table 1).
The first S–S bridge (Cys40–Cys132) connects the IL-22
N-terminal portion to the DE loop. The second one
(Cys89–Cys178) buckles helix C to helix F, and is pro-
posed to influence the F1 and F2 position, as well as the
helix F bend [26]. The presence of only one disulfide bond
in helix D region, instead of two as observed in IL-10,
gives more flexibility to helix E and F to fold back onto the
IL-22 A–D helices bundle, thus completing IL-22 mono-
meric structure formation [26].
Surface plasmon resonance studies [57] also confirmed
the IL-22 assembly as monomers. However, recent SAXS
data [58] revealed that at high concentrations, IL-22 is
capable of forming dimers or even tetramers in solution.
Nevertheless, the IL-22 dimers are formed by interactions
between individual monomers, which is very different from
the intertwined dimers observed for IL-10. An interesting
feature of the IL-22 SAXS envelopes is that the shape of
the IL-22 dimer is remarkably similar to the shape of the
IL-10, including the 90 opening angle formed between the
two monomer sub-units of the dimer. This might indicate
that the functionally relevant form of IL-22 that is recog-
nized by its cognate receptors at the cell surface may
indeed be a dimeric form [58]. However, the physiological
relevance of these findings still remains to be elucidated.
A possible connection between IL-22 dimerization and
human physiology [16] can be examined using via, for
example, peptide interference, perturbing the putative
interface of IL-22 dimerization with a small homolog peptide
that would inhibit homodimer formation [59]. Alternatively,
one might force receptor dimerization using a similar
approach to what has been described for the glycoprotein
gp130 [60]. In this study, gp130 was truncated 15 amino
acids above its transmembrane domain and the extracellular
portion replaced by the leucine zipper region of the human
c-jun gene, and stabilized by the addition of a disulfide bridge
[60]. Similar work could be done with IL-22R1, and its
interactions with IL-22 tested by JAK-STAT transcriptional
activation in cells expressing IL-10R2.
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IL-19
IL-19 is expressed in monocytes upon induction with
bacterial lipopolysaccharide (LPS), but not by T lym-
phocytes nor by NK cells [2, 9]. IL-19 expression showed
transcriptional variants [2, 61] that are detected 2–3 h
after induction, indicating a feedback role in inflamma-
tion, as observed for IL-10 [2]. The secreted protein has
21% amino acid identity with IL-10 [2] and shows dif-
ferent levels of glycosylation [61]. IL-19 signals through
IL-20R1/IL-20R2 complex [10], activating STAT3 tran-
scription factor [62]. At the mRNA level, the genes
encoding the IL-20R1/IL-20R2 complex appear to be
expressed in heart, lung, testis, adrenal gland, and skin,
suggesting that these tissues may be potential targets for
IL-19 [62]. However, many activities ascribed to IL-19
based on in vitro observation do not fit at all with the
tissue distribution of its receptor chains, raising questions
that need to be solved in order to draw conclusions about
the actual biological significance and mode of action of
this cytokine.
For instance, monocytes do not seem to express
IL-20R1 [9, 62], and yet IL-19 has been reported to
stimulate IL-6 and TNF release from monocytes, resulting
in TNF-a-mediated cell apoptosis [61], or to regulate its
own production and production of IL-10 [63]. Similarly,
IL-19 was reported to promote the maturation of T cells
towards Th2 polarization in mouse and human models
[64, 65]. IL-19 levels were reported to be two-fold higher
in patients with asthma as compared to healthy controls
and this correlated with the expression of IL-4 and IL-13,
involved in mucus secretion and airway hypersensitivity
[65].
IL-19 is also expressed in human injured arteries and in
vascular smooth muscle cells (VSMC) by inflammatory
cytokines, and IL-19 was reported to have antiproliferative
activity in VSMC [66]. In addition, through induction of
SOCS5 and inhibition of signal transduction, IL-19
expression in VSMCs was suggested to mediate protective,
autocrine response of VSMCs to inflammatory stimuli and
vascular injury [66].
A role of IL-19 in skin inflammation is more in line with
the expression pattern of its receptor complex, which is
expressed by keratinocytes [62–64]. In human psoriatic
lesions, IL-19 is expressed in epidermis above the dermal
papillae, as shown in the first report to demonstrate the
presence of this cytokine in keratinocytes [67]. Moreover,
the same work demonstrated that the cyclosporin A, and
calcipotriol, a derivate of vitamin D, both used in treatment
of psoriasis, abolished IL-19 mRNA expression. The pre-
cise involvement of IL-19 in psoriasis is still to be
determined, but this cytokine might represent a therapeu-
tical possibility for treatment of this disease.
IL-19 structural description The crystal structure of
IL-19 was solved by Chang and co-workers in 2003 and
deposited in the Protein Data Bank under code 1N1F [24].
Although Chang et al. named the pre helix A as helix A in
their paper, here we will adopt the same nomenclature used
in the IL-22 structure description. Interleukin-19 is struc-
turally organized by a unique six-helix bundle, formed by
helices A–F and the N-terminal helix preA (Fig. 2b).
Helices, A, C, D, and F form the characteristic cytokine
four-helix bundle and helix F displays the typical helix F
bend found in all other helical cytokines. As also observed
in the IL-10 3D structure, IL-19 also has a kink of helix A
[24]. Superposition of the IL-19 crystal structure with
IL-22 monomer or one of the domains of IL-10 leads to the
conclusion that they are relatively similar, with r.m.s.d. of
1.7 A˚
´
[24]. However, because of the orientation of IL-19
helix A and N-terminal region, IL-19 is more compact than
IL-10. IL-19 helix D also acquires a different position in
comparison to its counterpart in IL-10.
Three disulfide bonds are present in IL-19 and two of
those are structurally conserved in IL-10 (Fig. 2; Table 1).
IL-19 helix A, covering the molecule, is stabilized by a
disulfide bridge with the C-terminal portion of helix D
(Cys10–Cys103). The other two disulfide bonds (Cys57–
Cys109 and Cys58–Cys111) link the N-terminal portion of
helix C with the DE loop [13, 24]. The additional disulfide
bridge observed in the IL-19 DE loop (S–S interaction 3;
Fig. 2b, Table 1) is probably the main structural feature
that contributes to helices EF refolding onto helices A–D,
enabling the IL-19 fold as a compact monomer. Two
putative glycosylation sites are predicted in the IL-19
amino acid sequence, Asn38–Val39–Thr40, and Asn117–
Ala118–Tyr119 (Fig. 1a); although only glycosylation at
Asn38 side chain was found in the IL-19 crystal structure
[24].
An ionic interaction between Lys27 and Asp143, con-
necting helices A and F, is observed at the surface of IL-19
monomer. This interaction may contribute to IL-19 helix A
bend. It is important to note that the aspartate residue at the
helix F bend is conserved in all non-interferon IL-10 family
members, although in IL-22 and IL-10 crystal structures
the helix A Lys side chain is turned away from the helix F
(data not shown). Nevertheless, the conservation of
charged residues at the equivalent structural position on the
surface of all non-interferon members of IL-10 family may
be important for the recognition of their cognate receptors,
as will be discussed in the following chapters.
IL-20
IL-20 is a cytokine that bears 28% sequence identity to
IL-10 and is located in a chromosomal region (1q32) that
defines a cytokine cluster, comprised of IL-10, IL-19,
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IL-20, and IL-24 [68]. In contrast to IL-22, which is mainly
produced by TH17, NK, and NK-like cells, IL-20 is mainly
a monocyte and dendritic cell product, like IL-19 [9, 69].
Bacterial LPS also induces IL-20 expression in glial cells
in the brain [70]. By tissue microarray analysis performed
on human tissues, anti-IL-20 antibodies showed a positive
signal in several non-neoplastic tissue types that include
skin, small intestine, colon, liver, lung, spleen, kidney,
prostate, uterus, and brain [71].
IL-20 binds to two different receptor complexes desig-
nated type 1 and type 2 IL-20 receptor complexes and
consisting of the IL-20R1/IL20R2 or IL-22R1/IL-20R2,
respectively [68]. These receptor complexes are expressed
by keratinocytes in normal skin and at lower levels in other
tissues like ovary and placenta. The skin is considered so
far as the major target for IL-20, which induces hyper-
proliferation of keratinocytes [68]. Its overexpression in
transgenic mice resulted in neonatal lethality with aberrant
epidermal differentiation, resulting in lesions that mimic
psoriasis lesions in human patients [68]. Interestingly, both
IL-20 and IL-22 transgenic mice showed a similar psoria-
sis-like phenotype, have very similar effects on human
keratinocytes, and are coexpressed in human psoriasis
lesions [17], suggesting that their common receptor chain,
IL-22R1, might be a key target for psoriasis.
IL-20 structural considerations IL-20 shares high pri-
mary structure identity (44.1%) and similarity (52.4%)
with IL-19. The position of IL-20 cysteine residues is
equivalent to those in IL-19 and therefore it is likely that
the three S–S interactions found in IL-19 also exist in IL-20
[24]. Furthermore, IL-20 and IL-19 can both signal through
type 1 IL-20 receptor complexes composed of IL-20R1 and
IL-20R2 [10]. Both IL-19 and IL-20 are observed as
monomers in solution, even at high protein concentration
[72]. Collectively, these observations suggest that IL-20 is
structurally very similar to IL-19.
IL-24
IL-24 is a unique gene among those of the IL-10 family.
Originally cloned by a strategy of differentiation induction
subtraction hybridization (DISH), and named melanoma
differentiation-associated gene-7 (mda7) [73] because its
expression correlated with differentiation of melanoma
cells upon addition of IFN-b and mezerein, an antitumor
compound isolated from the Daphne species of plants [74].
This induction leads to growth suppression, melanin syn-
thesis, and widespread alterations in gene expression in
melanocytes [75]. Interestingly, the mda-7 gene was orig-
inally not recognized to encode a secreted protein and was
considered as a cancer-specific apoptosis-inducing gene in
which antitumoral activity has been intensely studied
[76–79].
In normal human tissue, IL-24 transcripts are detected in
spleen, thymus, and peripheral blood leukocytes, an indi-
cation of expression restricted to the immune system [80].
The mouse IL-24 orthogue, originally called FISP for
(IL-4-induced secreted protein), was described as a TH2
cytokine [81]. The rat orthologue of mda-7/IL-24, origi-
nally called c49a, is induced during wound repair [82],
suggesting that it may play the same kind of activity as
IL-22 or IL-20. In line with this hypothesis, IL-24 has
been described to bind to the same receptor complexes as
IL-20 [10, 83], and IL-24 transgenic mice recapitulate most
of the features of IL-20- and IL-22-transgenic mice,
namely neonatal lethality, epidermal hyperplasia, and abnor-
mality in keratinocyte differentiation, supporting a largely
redundant role in epidermal functions for IL-20, IL-22, and
IL-24, which seem to be IL-22R1-dependent [84].
The anti-tumor activity of IL-24 is more controversial
[85]. This effect does not correlate with the expression of
receptor complexes binding the secreted form of this pro-
tein, but an appealing hypothesis proposes that the mda-7
gene encodes both the secreted IL-24 form and a cyto-
plasmic isoform that is able to induce apoptosis in cancer
cells [86] but not in normal cells. This effect is observed
when the protein is expressed without its secretion signal
peptide. The mechanism by which IL-24 specifically
induces apoptosis of tumor cells but not in normal cells
remains to be described. Both the secreted and the signal
peptide-deficient IL-24 isoforms might accumulate in the
ER and Golgi compartments, thereby generating a signal
that induces ‘‘ER-stress apoptosis’’. Mitochondrial function
might be an important player in this signaling, either by
generating reactive oxygen species (ROS), release of
cytochrome c, or by loss of mitochondrial transmembrane
potential [87, 88].
IL-24 has been evaluated in several clinical trials. The
first clinical phase I study used direct intratumoral injection
of adenoviruses containing IL-24 in patients with advanced
carcinoma. The injection was well tolerated and IL-24
mRNA was detected in 100% of injected lesions, and this
expression induced apoptosis in a high percentage of the
cells [89, 90]. The desirable clinical response was observed
only with repetition of the injection. Similar to what is
found in culture cells, the results of these gene therapies
showed induction of tumor cell-specific apoptosis, antitu-
mor bystander effect, and also modulation of the immune
response. The clinical trials confirmed possibilities of
medical applications of IL-24 in cancer therapy. Further
investigations of the mechanisms by which IL-24 controls
cell apoptosis intracellularly might further improve the
clinical strategies of such treatments.
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Besides its direct antitumoral activity, IL-24 is able to
prevent angiogenesis, the growth of new blood vessels that
sustain tumor development and metastasis. This could be
achieved by two mechanisms, one through interaction with
IL-20R2/IL-22R1 receptor complexes, which affects
endothelial cells [91], and the other by inhibiting vascular
endothelial growth factor (VEGF) production by cancer
cells [92]. Finally, like IL-19, several reports have descri-
bed activities of the secreted form of IL-24 upon cell types
that are not supposed to express its functional receptor
complexes. For instance, IL-24 reportedly promoted the
secretion of TNF-a, IFN-c, and IL-6 from peripheral blood
mononuclear cells (PBMC) [93], and inhibits the plasma
cell differentiation program in human germinal center B
cells [94]. Further studies are definitely required to better
understand the molecular mechanisms underlying these
atypical effects of IL-24, and their potential pathophysio-
logical relevance.
IL-24 structural considerations Similar to IL-22 and IL-
19, the secreted form of human IL-24 is also glycosylated
and shows an apparent molecular mass of 25.30 kDa [73].
IL-24 has only two cysteines: Cys59, at the N-terminal
region, and Cys106, at helix C. The amino acid sequence
alignment of IL-24 with IL-19 and comparison with the
IL-19 crystal structure suggest that IL-24 most probably
monomerize in solution, particularly if Cys59 and Cys106
form a disulfide bond (reviewed in [13]). However, if
Cys106 from one IL-24 polypeptide chain interacts with
Cys106 from the other IL-24 polypeptide chain, IL-24 may
also form an intertwined dimer exemplified by IL-10
structure. Such helix C/helix C0 disulfide bond has already
been observed in the viral IL-10-related protein encoded by
the cytomegalovirus genome [95]. However, in this case,
Cys59 could not be involved in S–S bond formation, which
is unusual for helical cytokines [24].
The interferon lambda subgroup
IFN-ks, also called type III interferons, display a modest
but significant sequence identity with IFN-a2, a type I
interferon, mainly in what concerns the cysteine residues
positions. Although IFN-ks sequence similarity to IL-10
family members is even lower (*20%) than to IFN-a2 or
IFN-b (*30%), these cytokines are generally considered
to belong to the IL-10 family, mainly because they bind to
and signal via the class II cytokine receptor IL-10R2 [4, 5,
96]. In this review, we will follow this somewhat broader
definition of the IL-10 family, which appeared to be sup-
ported by the 3D structure of human IFN-k3 [23].
At the biological level, IFN-k1, IFN-k2, and IFN-k3
cytokines are more related to type I IFN, sharing the estab-
lishment of antiviral protection [97], antiproliferative [96],
and antitumor [98–100] activities (reviewed in [101]). These
cytokines activate the same JAK-STAT pathway, leading to
the activation of STAT1/STAT2/IRF9 transcription factor
complexes [4, 5, 96]. Therefore, both type I and type III IFNs
are involved in the induction of a common set of genes,
but differ by the duration of signaling and the tissue speci-
ficity of the expression of their respective receptors [102,
103]. Likewise, analysis of gene expression using DNA
microarrays indicated similar induction in hepatocyte and B
cell lines stimulated with either IFN-k1 or IFN-a cytokines,
and this involves phosphorylation of STAT proteins STAT1,
-2, -3, -4, and STAT5 [104].
On the cell surface, IFN-ks bind to the IFN-kR1 receptor
(also called IL-28R1) associated with the common receptor
IL-10R2 for signaling, which is also used by IL-10, IL-22,
and IL-26 [105]. The tissue and cell specificities of the
responses to systemic IFN-a/b and IFN-k have been
recently compared by the group of Michiels [106]. The
response to IFN-k correlated with expression of IFN-kR1.
The IFN-k response was prominent in the stomach, intes-
tine, and lungs, and was mainly restricted to epithelial
cells. In contrast, the response to IFN-a/b was more
ubiquitous and was observed in various cell types [106].
These results raised the hypothesis that the IFN-k system
probably evolved to specifically protect epithelia. Thus,
IFN-ks might represent key contributors to the prevention
of viral invasion through skin and mucosal surfaces,
whereas IL-22 might be a key mediator of anti-bacterial
and anti-fungi responses at the very same surfaces of the
body, as discussed above.
The antiviral protection conferred by IFN-ks has been
confirmed in various cell lines, including HeLa, HuH7
hepatoma, and HT-29 colon epithelial cells and with dif-
ferent viruses, including Sindbis virus, dengue virus,
vesicular stomatitis virus, and human cytomegalovirus [97,
107]. Mouse deficient in the gene encoding IFN-kR1,
recently allowed to demonstrate the respective roles of type
I and type II IFN in an influenza infection model. Mice
lacking functional IFN-kR1 were only slightly more sus-
ceptible to influenza virus than wild-type mice. However,
mice lacking functional receptors for both IFN-a/b and
IFN-k were hypersensitive and even failed to restrict usu-
ally non-pathogenic influenza virus mutants lacking the
IFN-antagonistic factor NS1 [108].
When using interferons as therapeutic agents, the most
important limiting factor is specificity. Indeed, IFN-a has
been used for therapy of carcinomas but this strategy has a
large range of side effects, which include myelosuppres-
sion [109]. Because of the restricted tissue expression of
the IFN-kR1 receptor, IFN-ks might be used as therapeutic
agents without this type of toxicity. Hepatitis C virus could
be an important target of IFN-ks, as suggested by genetics
studies showing that genetic variation in the gene encoding
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IFN-k3 predicts hepatitis C treatment-induced viral clear-
ance [110–113]. Although mouse liver cells might not
respond to IFN-ks, it has been shown that IFN-k1 in
combination with either IFN-a or IFN-c is able to block
hepatitis C virus replication in human hepatocytes, indi-
cating that IFN-ks may be used for treatment of this disease
[114].
IFN-k3 structural studies Very recently, Gad et al. [23]
solved and published the human IFN-k3 crystal structure
(PDB ID 3HHC). Analysis of IFN-k3 X-ray structure
reveals that this type III interferon is more structurally
related to IL-10 family members than to other interferons.
Furthermore, IFN-k3 is very similar to IL-22, which dis-
plays parallel functions in skin as discussed above [23].
IFN-k3 contains the six a-helical domain (helices A to F),
characteristic of all class II cytokines. The four-helix
bundle, typical for the IL-10 family, is found in the IFN-k3
core. This comprises helices A, C, D, and F. The later
helix, helix F, also has the characteristic bend found in
other IL-10 family members.
Seven cysteine residues are found in IFN-k3 structure,
and six of these form three disulfide bonds (Fig. 2b;
Table 1). Cys4 is bound to Cys103, connecting the N-ter-
minal region to helix D. It is important to note that this S–S
bond is conserved among the IL-10 family members.
However, the other two S–S bridges have no equivalents in
other IL-10 family proteins. The Cys38–Cys136 bond,
which connects the AB loop with the beginning of helix F1,
is restricted to IFN I and IFN III groups; whereas Cys155–
Cys162 bridge, found in the end of helix F2, is only
observed in the IFN-ks group (with the exception of the
human IFN-k1) [23].
IFN-k1 and IFN-k2: structural considerations Since
IFN-k2 shares 94% of amino acid sequence identity with
IFN-k3, it is to be expected that their 3D structures are
almost identical, including the disulfide bonds pattern [23].
At the same time, IFN-k1 has very high amino acid
sequence identity with IFN-k3 (69%), therefore, it is highly
probable that IFN-k1 is also structurally very similar to
IFN-k3 [23]. The structural organization of IFN-k3 [23]
and previous experimental observations [13] suggest that
IFN-ks form monomers in solution.
The IL-10 family members that form intertwined
dimers: IL-10 and IL-26
IL-10
Originally termed cytokine synthesis inhibitor factor [115],
interleukin-10 (IL-10) is a notably important cytokine with
pleiotropic immunoregulatory effects. It was first identified
as a product of T-helper type 2 (Th2) cells, but since its
discovery, a large variety of cells were identified as the
source of IL-10, which include macrophages, monocytes, B
cells, dendritic cells (DC), CD8? T cells, regulatory T cells
(Tregs), Th1 cells, and Th17 cells [116]. After secretion, on
the surface of its target cells, dimeric IL-10 molecules bind
to the high-affinity IL-10R1 receptor and this complex
recruits the low-affinity receptor IL-10R2 [117]. This
sequential mechanism allows the intracellular activation of
Janus kinase 1 (Jak1) and also tyrosine kinase 2 (Tyk2).
Once activated, these kinases phosphorylate signal trans-
ducer and activator of transcription proteins (STAT1 and
STAT3), which are the main transcription factors involved
in IL-10-mediated immune responses [1]. In turn, the
transcription factors activate the expression of SOCS-3
(suppressor of cytokine signaling-3) and also SOCS-1
genes, which results in the inhibition of JAK-STAT-
dependent signaling [118].
The immunomodulatory effects of IL-10 are complex,
given that this cytokine presents both antiinflammatory
and immunostimulatory activities. Its anti-inflammatory
activity can be illustrated by a long list of genes that are
downregulated by IL-10 including IFN-c and IL-2 by
Th1 lymphocytes, Th2-cell derived cytokines (IL-4 and
IL-5), IFN-c and TNF-a by NK cells, and proinflam-
matory cytokines (IL-1b, TNF-a, and IL-6) by
mononuclear phagocytes [1], while IL-10 promotes the
production of cytokine antagonists such as IL-1RA [119]
and soluble TNF p75 receptors [120]. It was also
described that IL-10 molecules are capable of inhibiting
the production of chemokines such as MIP-1a (monocyte
inflammatory protein-1a), IL-8, and RANTES (regulated
on activation, normal T expressed and secreted) [121,
122]. Moreover, IL-10 inhibits the expression of the
major histocompatibility complex (MHC) class II mole-
cules, intercellular adhesion molecule 1 and costimu-
latory molecules CD80 and CD86 in antigen-presenting
cells (APC) [123].
Immunostimulatory effects elicited by IL-10 include
promotion of the survival of human B cells, which
occurs simultaneously with increasing levels of anti-
apoptotic bcl-2 protein [124] and an increase of NK cell
activity [125]. Increased IL-10 production has been
observed in systemic lupus erythematosus (SLE) patients
and serum IL-10 values reflect SLE disease activity,
suggesting that overexpression of IL-10 might play a
pathogenic role in severe lupus disease [126]. In vitro,
interleukin-10 blockade corrects impaired cellular
immune responses of SLE patients [127], suggesting that
anti-IL-10 antibodies might represent a meaningful
therapeutic approach in this disease. Indeed, clinical tri-
als already tested murine anti-IL-10 for treatment of
lupus erythematosus during 3 weeks [128]. This
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treatment resulted in rapid and long-lasting amelioration
of the disease.
Altogether, IL-10 effects predominantly limit inflam-
matory responses in order to minimize tissue damage
initiated by microorganism challenges. Such an anti-
inflammatory activity represents an attractive perspective
for inflammatory diseases such as rheumatoid arthritis. In a
murine model of collagen-induced arthritis, injection of
human adenovirus type 5 expressing IL-10 had a protective
effect in the knee joint. This overexpression altered TNF-a
and IL-1a production in inflamed synovium and probably
has an effect in collagen arthritis in the knee [129]. These
results suggest that IL-10 cytokine is likely to be suitable
for treatment of rheumatoid arthritis.
IL-10 structural description The crystal structure of
IL-10 was the first reported three-dimensional structure of
an IL-10 family member [6, 7], which revealed an unex-
pected similarity with the IFN-c 3D fold [7]. Differently
from what is observed for the IL-19 subfamily members,
IL-10 forms intimate intertwined homodimers. Each IL-10
subunit has two disulfide bonds connecting the DE loop to
helix C (Cys62–Cys114) and to the N-terminal region
(Cys12–Cys108). These S–S interactions, mainly the one
between Cys62 and Cys114, promote a certain degree of
rigidity of helix E. As a consequence, helices E and F fold
as an independent IL-10 domain that makes a right angle
with the other domain composed of helices A–D [6, 7, 130,
131]. This promotes two IL-10 polypeptide chains to join
together to form an intertwined V-shaped dimer. Each of
the two domains of the IL-10 dimer contains four helices
from one polypeptide chain (helices A–D) and two other
helices from the other polypeptide chain (helices E0 and F0,
Fig. 2a). In IFN-c, a short DE loop is the main reason for a
similar structural architecture; however, in IFN-c, the angle
formed between the two monomers is *60 [131–134]. In
IL-10, the 90 inter-domain angle allows helix C to be
exposed, creating a potential interaction site with its
receptors [6].
The quaternary structure arrangement of IL-10 in the
form of intimate intertwined dimer is one of the main
structural differences that distinguishes it from the IL-19
sub-family members (reviewed in [13]). However, similar
to all other class II cytokines, IL-10 forms a four-helix
bundle (helices A, C, D, and F0), which is characteristic
feature of this class of proteins. These four helices form an
extensive hydrophobic core that accounts for 85% of all the
hydrophobic residues of IL-10 [130].
In IL-10, helices A, C, and F display significant bends,
which were inferred to improve the IL-10 fold [6]. Helix A
is kinked at the residues Leu23 and Phe30, which disrupts
the hydrogen bond pattern of helix A, forming a new net-
work with the residues of helix D. Helix C contains the
well-conserved Pro78 residue, found in all known IL-10
amino acid sequences. Pro78 is responsible for a 23 bend
of helix C, which is centered at Val-76 and leads to the
exposure of Glu75 side chain [6]. The conserved kink at
helix F is found in all other IL-10 family members with
known 3D structures. In IL-10, helix F is turned *129,
exposing the side chain of Glu142 and braking helix F in
helix F1 and helix F2, in exactly the same way as observed
for IL-22.
The IL-10 helix F presents a canonical IL-10 family
sequence signature K A/S X G/S E X D X X (where X is a
hydrophobic residue), also found in IL-22. However, there
are several amino acid substitutions in IL-10 primary
structure in comparison to the same region of IL-22 amino
acid sequence (Fig. 1a).
IL-26
IL-26 was found in a screen searching for phenotypic
alterations of T-cells upon simian rhadinovirus herpesvirus
saimiri (HVS) infection [135, 136]. This interleukin has
47% similarity to IL-10 and it is secreted as intimate
homodimers in solution as also found for IL-10 [137].
IL-26 secretion is not observed in B cells [138] but it is
detected by RT-PCR in T and NK cells [9] and also in
various T-cell lines transformed with HVS, but not in
Jurkat, HeLa, SupT1, MT2, HuT-102, C91PL, B/JAB, and
Tera2 cells [138].
The target cells of IL-26 are colon carcinoma cells and
keratinocytes [139]. A typical feature of IL-26 is its high
affinity for heparin that suggests similar affinity for gly-
cosaminoglycans moieties on proteoglycans that could
enrich the cytokine at the cell surface and work as IL-26
co-receptors. Enriched cytokines would bind to IL-20R1
and IL-10R2 receptors combination [139, 140] and activate
STAT1 and STAT3 transcription factors. This particular
receptor combination is what gives IL-26 its specificity
since the other IL-10 family members are not able to signal
via this complex. Moreover, this specificity is determined
by IL-20R1 expression in specific tissue and not by
IL-10R2, which is broadly expressed.
The participation of IL-26 in human diseases remains
unclear, and the absence of any IL-26 orthologue in the
mouse genome does not facilitate the evaluation of its
biological activities. IL-26 maps to human chromosomal
region 12q15 in a close vicinity to IL-22 and IFN- c [138].
Polymorphisms in this region are related to sex bias in
rheumatoid arthritis [141]. A more compelling result
indicates that IL-26 protein expression is higher in patients
with Crohn’s disease [142]. IL-26 stimulates the expression
of proinflammatory mediators (TNF-a e IL-8) in IECs
(intestinal epithelial cells) [142]. Moreover, overexpression
of IL-26 in colonic lesions of patients with Crohn’s disease
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is correlated to IL-22 and IL-8 production, which are also
involved in inflammation. Whether IL-26 plays an actual
role in the pathogenesis or just represents a useful marker
for inflammatory bowel disease remains to be established.
IL-26 structural considerations IL-26 has 24.7% amino
acid sequence identity and 47% similarity to IL-10. Based
on the highly conserved cysteine positions found between
IL-26 and IL-10, as well as in vitro analysis of recombi-
nant IL-26 [137, 138], it was proposed that IL-26 forms
IL-10-like intercalated homodimers [138].
Cell signaling by IL-10 family members
The signaling of IL-10 family members is initiated by the
recognition of a soluble interleukin by specific transmem-
brane receptors. IL-10 family members bind to the
extracellular domain of two transmembrane receptors,
forming a ternary complex constituted of the interleukin,
one receptor chain with a long cytoplasmic domain, and
one receptor chain with a short cytoplasmic domain.
Both receptor chains possess cognate Janus-family
tyrosine kinases (JAK1, JAK2, or Tyk2) associated with
their intracellular domain. Interleukin binding to the two
specific receptors activates JAK proteins, either by allow-
ing ideal protein/protein contacts, or by inducing
conformational changes (Fig. 3). It is important to note that
a single JAK molecule cannot phosphorylate any specific
residues on its own chain, due to intra-chain mobility
problems (reviewed in [143]). However, upon the ternary
IL/IL-R1/IL-R2 complex formation, the two JAKs mole-
cules associated with IL-R1 and IL-R2 can phosphorylate
each other, which increases their phosphorylation activity.
The activated JAKs then phosphorylate several residues in
the receptor chain, signaling to signal transducers and
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Fig. 3 Schematic representation of IL-10 family members signaling
pathway, based on the IL-22 set of receptors. 1 Inactivated long- and
short-chain class II cytokine receptors are bound to Janus-family
tyrosine kinases (JAK1 and Tyk2). Inactivated STAT homodimers are
found in the cytoplasm. 2 Interleukin binding on the extracellular
portion of R1 and R2 activates intracellular JAK/Tyk phosphory-
lation. Tyrosine residues on either Jak/Tyk and on the receptors are
phosphorylated. However, a soluble decoy receptor (IL-22BP) can
interact with the IL-22 lacking transmembrane receptor activation.
3 STATs are recruited and phosphorylated, forming activated STAT
dimers. 4 STAT dimers migrate to the nucleus activating cytokine
specific induced genes
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activator of transcription (STATs), which results in phos-
phorylation of specific STAT residues.
The phosphorylated STATs form homo- or heterodimers
then migrate to the nucleus where they specifically activate
transcription. Phosphorylated STAT dimers specifically
bind to GAS (IFN-c activation site), a palindromic
enhancer with a consensus sequence (N5-GAS) found in
many promoters of cytokine-responsive genes [143, 144]
(Fig. 3). In the case of signaling by IFN-ks, a complex
consisting of STAT1, STAT2, and p48 (IRF9), termed
ISGF3, binds to interferon-stimulated response element
(ISRE) promoting interferon-specific gene transcription
[145, 146]. All other members of the IL-10 family activate
mainly STAT3.
Receptors involved in IL-10 family members signaling
As alluded to above, a ternary complex formation involv-
ing the interleukin and its cognate type 1 and type 2
receptors is a crucial step in activation of the effective
interleukin signaling. All IL-10 family members signal
through the combination of a long chain (IL-10R1,
IL-22R1, IL-20R1, or IFN-kR) and a short-chain (IL-10R2
or IL20-R2) class II cytokine receptor (reviewed in [143,
145], Table 2). Additionally, IL-22 can interact with high
affinity with the IL-22 binding protein (IL-22BP), a soluble
type 1 receptor that can antagonizes IL-22 signaling by
impairing its interaction with the transmembrane receptor
IL-22R1 [147]; Fig. 3.
The class II cytokine receptor family (CRF2) comprises
transmembrane glycoproteins with a single membrane
spanning region of 20–25 amino acid residues. The CRF2s
can be separated into three domains, the extracellular
(*200 amino acids long), the intracellular (*60 to *300
amino acids long, for the short- and long-chain receptors,
respectively) and the transmembrane domain. Although
low residue conservation is observed in the transmembrane
and intracellular domains of the CRF2s, several important
features are preserved in the extracellular domain.
The extracellular portion of CRF2s contains two highly
conserved disulfide bridges and several conserved proline
and tryptophan residues. This domain is generally orga-
nized into two fibronectin type III (FNIII) sub-domains in
tandem, which have an immunoglobulin-like fold with
seven b-strands organized in two b-sheets (reviewed in
[143, 145]). The extracellular domain of class II cytokine
receptors is responsible for its ligand binding and speci-
ficity. There is a partial overlap of CRF2s combination in
IL-10 family signaling, but specificity is still attained by a
specific receptor and/or interleukin expression by different
cell types [145, 146].
The cytoplasmic domain of cytokine receptors generally
contains short a-helices organized in boxes named box I
and box II close to the transmembrane regions. These
‘boxes’ are responsible for stable interactions with JAKs
[148] (Table 3). Several tyrosine residues are found in the
cytokine receptor cytoplasmic portion, and these are
phosphorylated by the JAKs associated kinases after
receptor stimulation (reviewed in [143]). JAK phosphory-
lation leads to STAT activation, mostly STAT1 and
STAT3, but STAT5 phosphorylation can also be induced
by IL-10, IL-22 and the IFN-k group that also signals
through STAT2 (reviewed in [143]). A unique character-
istic of the IL-22R1 chain is that the C terminus of this
receptor chain recruits in a tyrosine-independent manner
the coiled-coil domain of STAT3. Mutation of all IL-22R
cytoplasmic tyrosines did not abolish activation of STAT3
in response to IL-22. By contrast, deletion of the C-ter-
minal part of IL-22R1 dramatically decreased its ability to
activate STAT3 and to mediate IL-22 activity in cell lines,
demonstrating that pre-association of STAT3 with this
cytokine receptor, independent from the interaction
between the Src homology 2 domain and phosphotyrosines,
is required for its full activity [149].
In terms of crystal structures, limited information is
currently available about IL-10 family members’ binaryTable 2 The IL-10 members and their transmembrane receptors
IL-10
member
Type 1
receptor
Type 2
receptor
Reference
IL-10 IL-10R1 IL-10R2 [11, 12]
IL-19 IL-20R1 IL-20R2 [10, 164]
IL-20 IL-20R1
IL-22R1
IL-20R2
IL-10R2
[10, 68, 164]
IL-22 IL-22R1
IL22BP
IL-10R2 [154, 155, 157,
165]
IL-24 IL-20R1
IL-22R1
IL-20R2
IL-20R2
[10, 83, 164]
IL-26 IL-20R1 IL-10R2 [139, 140]
IFN-ks INF-kR1 IL-10R2 [4, 145]
Table 3 Cytokine class II receptors involved in IL-10 family mem-
bers signaling and their associated Janus-family thyrosine kinases
(JAKs)
CRF2 JAK associated Reference
IL-10R1 JAK1 [157]
IL-20R1 JAK1, JAK2 [166]
IL-22R1 JAK1, JAK2 [157]
IFN-kR1 JAK1 [167, 168]
IL-10R2 Tyk2 [157]
IL-20R2 JAK2 or Tyk2 [166]
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complexes, and no crystallographic data exists for the
ternary complexes to date. Overall, the crystal structures of
IL-10/IL-10R1 [117] and IL-22/IL-22R1 [27, 28] binary
complexes have already been solved. Very recently, the 3D
structure of IL-22 bound to its decoy soluble receptor
IL-22BP has also been determined [150].
Based on the available crystal structures of IL-10s
binary complexes, here we will discuss the interleukin/
receptor interfaces, conformational changes caused by the
type 1 receptor binding and the potential type 2 receptor
binding sites formed upon the binary complex formation.
Since the ternary complex’s structures are not yet avail-
able, we will refer to theoretical models and site-directed
mutagenesis analysis to discuss the second receptor-
binding interfaces and the importance of cytokine con-
formational changes for the ternary complex formation.
We will also review the published data that focused on
the interleukin/receptor hotspots in the other IL-10 family
members.
Binary complexes with known three-dimensional
structure
IL-10 and IL-22 binary and ternary complexes have been
extensively studied over the last decade [27, 28, 57, 150–
153]. However, due to the intrinsic difficulties to work with
the entire transmembrane receptor, these studies were
mostly conducted with the receptor extracellular domain. It
has been shown that IL-10 and IL-22 display high affinity
for their long-chain cognate receptors (IL-10R1 and IL-
22R1, respectively); while the interaction of the free
interleukin with the second receptor chain, IL-10R2, is
weak [57, 151].
It was also demonstrated that the first binary complex
formation facilitates interactions with IL-10R2. Experi-
mental data obtained using surface plasmon resonance
(SPR) demonstrated that the dissociation constant of the
soluble sIL-10R2 and IL-22 complex is 120 lM, as com-
pared to 14.4 lM for the IL-22/IL-22R1 binary complex,
[151]. In a similar way, the dissociation constant for
IL-10R2 and IL-10 is in the millimolar range whereas that
of IL-10/IL-10R1 binary complex is in the micromolar
range [57]. These findings suggest that conformational
changes of the cytokines, caused by the first receptor
binding, and/or the formation of new interaction sites on
the binary complex, may contribute to the second receptor
binding, in a sequential cooperative process involving the
binary and ternary complexes formation.
The IL-22/IL-22R1 structure and interfaces
Two crystal structures of IL-22 complexes with the soluble
extracellular domain of IL-22R1 (sIL-22R1) independently
determined by two different groups have been reported
recently (PDB ID: 3DGC [27] and 3DLQ [28]). Both
structures revealed that the sIL-22R1 is composed of two
fibronectin type III (FBN-III) domains, termed D1 (N-ter-
minal) and D2 (C-terminal) [27, 28]. The D1 and D2
domains make an angle of approximately 120 to each
other [28]. Each IL-22R1 domain presents seven b-strands
(A, B, C, C0, E, F and G) forming a sandwich of two
antiparallel b-sheets connected by small helix and loops. In
addition, IL-22R1 three-dimensional structure contains a
small N-terminal helix (Fig. 4a).
Residues from IL-22 helix A, AB loop, and helix F
make contacts with IL-22R1 loops L2 to L6, which are
located at the interface of D1 and D2 domains. A total of
25 amino acid residues are involved in IL-22 and IL-22R1
interactions [28], and these are mainly mediated by polar
contacts. Two sub-sites can be recognized in the IL-22/
IL-22R1 interface, namely site 1a and 1b [27]. Site 1a is
characterized by hydrogen bond and ionic interactions
between IL-22 and the D1 N-terminal domain from
IL-22R1. An extensive water-mediated hydrogen bond
network is present between residues from IL-22R1 L2–L4
loops and residues from IL-22 AB loop and helix F. The
IL-22R1 Tyr60 (loop L2) and the IL-22 Arg73 (AB loop)
residues are found at the center of two discernible clusters
of this network, located, respectively, at the upper and
lower portion of the site 1a. Residue Tyr60 inserts itself
into a cleft formed by IL-22 helices A and F and the AB
loop, contacting IL-22 residues from helix F1 (Lys162 and
Glu166) and AB loop (Asp67, Asp71, and Arg73). It is
important to note that Lys162 and Glu166 make part of the
IL-10 signature (KAIGELDLL). IL-22R1 residues Glu62,
Ser64, and Gly61 from loop L2 and Tyr93 and Arg112
from loop L4 also participate in this network. On the other
portion of site 1a, Arg73 side chain is stabilized by a water
molecule that also interacts with the IL-22R1 Tyr60 main
chain oxygen atom. Arg73 projects itself into a cluster of
water molecules and polar side chains. Arg73, Asp168
(helix F2), and Gly165 (helix F bent) from IL-22 partici-
pate in the hydrogen bond network by interacting with
residues from IL-22R1 loop L3 (Glu90, Thr89 and Lys88)
and loop L4 (Ser114). Additionally, three ionic contacts are
found in IL-22/IL-22R1 site 1a, involving residues Asp71,
Asp67, and Arg112 from IL-22 and residues Lys58,
Arg112, and Glu90 from IL-22R1 (connected by the red
lines in Fig. 4a).
On the other hand, the IL-22/IL-22R1 interactions at site
1b are less extensive, but nevertheless appear very
important for IL-22 conformational changes induced by
IL-22R1 binding. A hydrogen bond network is formed,
which involves IL-22 residues from helices A and F and
IL-22R1 residues from loops L5 and L6 in its D2 C-ter-
minal domain. Phe47 and Thr53 from IL-22 helix A
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interact with Thr207 from IL-22R1 loop L6 through a
water molecule, whereas the IL-22R1 Thr207 side chain
interacts directly with the Arg175 side chain located on
IL-22 helix F. Phe47, Gln49, and Thr53 from IL-22 helix
A interact with the backbone oxygen from Pro206 on
IL-22R1 loop L5. A hydrophobic cluster, involving IL-22
residues positioned at helix F (Met172 and Arg175) and
IL-22R1 residues from loop L6 (Thr207 and Trp208), also
contributes to IL-22/IL-22R1 binding and recognition.
Mutagenesis analysis revealed that IL-22R1 residue
Tyr60 is essential for IL-22/IL-22R1 complex formation
[28]. Mutation of Tyr60 to either Arg or Ala impaired
STAT3-dependent responses in HEK-293 cells expressing
the IL-22R1 point mutants [28]. On the other hand, cells
expressing the IL-22R1 Lys58Ala point mutant still
responded to IL-22 stimulation, however with a 100-fold
decrease in specific activity [28]. This observation suggests
that lost of ionic interaction between IL-22R1 Lys58 and
IL-22 Asp71 is important, but somewhat less fundamental
for IL-22/IL-22R1 complex formation.
The IL-22/IL-22BP structure and interfaces
In 2001, a gene encoding a protein of 231 amino acid
length and sharing 33% amino acid identity with the
extracellular domain of IL-22R1 has been identified [154,
155]. The protein, lacking the transmembrane and cyto-
plasmic domains of typical class II cytokine receptors,
displays structural homology with the extracellular portion
of IL-22R1 [155]. The purified protein migrated as a 35 to
45-kDa band on SDS-PAGE gels, suggesting existence of
glycosylation. Indeed, bioinformatics analysis predicts five
N-glycosylation sites (Asn-X-Thr/Ser) based on the protein
amino acid sequence. The recombinant protein binds to and
inhibits IL-22 activity in hepatocytes and intestinal epi-
thelial cells [155]. Furthermore, cross-linking experiments
revealed that the protein binds IL-22 and prevents the
formation of IL-22/IL-22R1/IL-10R2 ternary complex
[154]. This protein was termed IL-22 binding protein
(IL-22BP) [154, 155].
IL-22BP has higher affinity to IL-22 (*1 pM) than
IL-22R1 (*1 nM) and does not bind any other family
member, such as IL-10, IL-19, IL-20, or IL-24. Thus, it
seems that the IL-22BP expression is one of the mecha-
nisms to specifically regulate IL-22 activity and probably
modulates local inflammation [27, 57].
The IL-22BP human gene is organized in six exons and
located on chromosome 6, 100 kb apart from IL-20R1 and
24 kb from the gene encoding IFN-cR1 [147, 154, 155].
Tissue distribution of IL-22BP mRNA showed the highest
expression levels in breast, placenta, and skin; but high
expression was also found in spleen, gastrointestinal tract,
and lungs, and lower levels were detected in brain, heart,
thymus, pancreas, testis, and prostate [147, 155]. Nothing
is currently known about the distribution of the protein, its
concentration in various body fluids, and its correlation
with pathophysiological processes.
The structure of IL-22BP bound to IL-22 has been
solved very recently ([150], PDB entry 3G9V). Not sur-
prisingly, the overall IL-22BP structure organization is
very similar to the extracellular part of IL-22R1
(r.m.s.d. = 1.68 A˚). IL-22BP molecule folds in an
L-shaped structure consisting of two FBN-III domains (a
N-terminal D1 domain and a C-terminal D2 domain),
connected by a small 310 helix and making a 125 opening
angle with respect to each other. Each FBN-III domain
forms a b-sandwich composed by two anti-parallel sheets
formed from seven b-strands, named A, B, E and C, C0, F,
and G (Fig. 4b).
IL-22BP D1 domain is more similar to IL-22R1 D1
(r.m.s.d. = 0.81 A˚) than are their D2 domains
(r.m.s.d. = 3.57 A˚). This is in line with the lower amino
acid sequence identity between IL-22R1 and IL-22BP at
the D2 domain regions [150]. There are also structural
divergences in the disulfide bond pattern between these two
receptors within the D2 domain region. In IL-22BP,
Cys206 (b-strand F) is probably connected to Cys227
(b-strand G), although Cys227 has not been observed in the
electron density of the IL-22/IL-22BP crystal complex.
However, in IL-22R1, Cys128 (b-strand A) is linked to
Cys217 (b-strand G). This is a particularity of the IL-22R1,
since the disulfide bond pattern found in IL-22BP D2
domain is conserved in all other class II cytokine receptors.
Another disulfide bond found in IL-22BP structure occurs
in the D1 domain: Cys78 interacts with Cys86, connecting
strands C0 and E. Equivalent S–S bridges are found in the
IL-22R1 and IL-10R2 D1 domains.
Comparison of IL-22/IL-22BP and IL-22/IL-22R1
crystal structures show that both receptors display over-
lapping IL-22 binding interfaces, which is consistent with
the inhibitory role played by IL-22BP. As observed for the
IL-22/IL-22R1 and IL-10/IL-10R1 complexes, IL-22BP
contacts IL-22 using loops L2 to L6 forming two distinct
binding interfaces: site 1a and site 1b.
Residues from IL-22BP loops L2–L4 contact IL-22
residues from loop AB (Asp67, Thr70, Asp71, Val72,
Arg73, Glu77) and helix F1 (Lys162, Gly165, Glu166),
forming the IL-22/IL-22BP site 1a. Tyr67 from IL-22BP
loop L2, which is equivalent to IL-22R1 Tyr60, inserts
itself into a cleft formed by residues from IL-22 helices A
and F1 and the AB loop, including Lys162 and Glu166 that
are part of the IL-10 family signature. IL-22BP Tyr67
makes direct contacts with Asp67, Asp166, and Lys162
side chains and Val72, Arg73, and Thr70 main chains.
Furthermore, water mediates the interaction between
IL-22BP Tyr67 main chain oxygen atom and IL-22 Glu77
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side chain. Lys65, Glu97, and Arg119 from IL-22BP loops
L2, L3, and L4, respectively, form ionic interactions with
IL-22 residues Asp71, Arg73 and Asp67 located on the AB
loop (Fig. 4b).
On the other hand, there are fewer polar contacts at the
IL-22/IL-22BP site 1b. IL-22BP residues Met215 and Leu216
from the loop L6 interact with IL-22 residues from the helices
pre-A (Phe47) and A (Thr53 and Asn54). Interestingly,
IL-22BP residue Glu168 and IL-22 helix F2 residue Arg175
form an ionic interaction that is not observed in the IL-22/
IL-22R1 site 1b interface, due to an alternative side chain
conformation of Arg175 in the IL-22/IL-22R1 binary com-
plex structure [28]. Additionally, IL-22BP Trp123, Trp124,
Met215, and Leu216 are closely positioned to the hydropho-
bic IL-22 residues Phe57, and Met172, thus forming a
hydrophobic cluster that further contributes to IL-22/IL-22BP
stabilization at the site 1b (Fig. 4b).
Structural analysis of the IL-22/IL-22BP interface and
its comparison to IL-22/IL-22R1 binary complex revealed
a number of structural divergences concerning their bind-
ing interfaces. Overall, the IL-22BP polar contacts with
IL-22 are higher in number and smaller in distances than
the observed to IL-22R1 and these are mainly direct instead
of water mediated contacts. Furthermore, IL-22/IL-22BP
complex contains a larger hydrophobic cluster centered at
site 1b as compared to IL-22/IL-22R1. These structural
differences might explain dissimilarities in affinity of IL-22
binding to IL-22BP and IL-22R1.
The critical residues identified from the structural
analysis of the IL-22/IL-22BP complex allowed the design
of site-directed mutagenesis for functional studies [89].
Two IL-22BP residues (Tyr67 and Arg119) were chosen
due to their participation in important IL-22/IL-22BP
interactions. Both IL-22BP Tyr67 and Arg119 point
mutants completely abolished IL-22 binding. Mutations in
equivalent residues of IL-22R1 led to similar results. These
findings indicate that Tyr67 (Tyr60 in IL-22R1) and
Arg119 (Arg112 in IL-22R1) are crucial for IL-22BP and
IL-22R1 binding to IL-22 [28, 150].
The IL-10/IL-10R1 structure and interfaces
The three-dimensional structure of IL-10 in complex with
its cognate receptor sIL-10R1 was solved by Josephson and
co-workers in 2001 (PDB ID 1J7V [117]). Despite the low
amino acid sequence identity between IL-22R1 and
IL-10R1, they are structurally similar. The main differ-
ences observed between these two structures are related to
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the orientation of the IL-10R1 D2 domain with respect to
its D1 domain. The IL10R1 D1 domain is rotated about 30
with respect to the D2 domain in comparison to the
orthogonal mutual orientation of D1/D2 domains of the
IL-22R1 structure [27, 28]. Furthermore, IL-10R1 contains
a WSXWS-like motif, consisting of residues His87, Ser88,
Gln89, Trp90, and Thr91, in its D1 domain (Fig. 4c). The
WSXWS motif is found in class 1 cytokine receptors [156].
In IL-10R1, the HSQWT sequence divides the G strand of
D1 domain in two equivalent sub-parts, named G1 and G2
[117]. Differently from the classic class 1 receptors con-
taining the WSXWS sequence, the hydrogen bond pattern
of the IL-10R1 positions the G1 and G2 segments parallel
to each other, orienting the L2 and L4 loops position. It was
proposed that the residues in or close to the WSXWS-like
motif may influence domain orientation, as well interleu-
kin/receptor interactions [117]. It is important to note that,
in IL-22R1, there is no equivalent sequence and the G
strand is continuous (Fig. 4a). Furthermore, the disulfide
bonds found in IL-10R1 are not structurally equivalent to
those observed in IL-22R1.
Despite the low sequence identity and several secondary
structure mismatches, the overall IL-10/IL-10R1 interac-
tions are very similar to those found in the IL-22/IL-22R1
complex. The same two interfaces described to IL-22/IL-
22R1, sites 1a and 1b, occur in the IL-10/IL-10R1 com-
plex, involving structurally equivalent regions. Site 1a
includes the IL-10R1 loops L2-L4 and IL-10 AB loop and
helix F; whereas site 1b is composed by the IL-10R1 loops
L5, L6, and the N-terminal portion of helix A and the
C-terminal region of IL-10 (Fig. 4c).
The main interactions observed in IL-22/IL-22R1 site 1a
are conserved in the equivalent site of the IL-10/IL-10R1
crystal complex. IL-10 Tyr43 play the role of IL-22 Tyr60
being positioned into the cleft formed by the interleukin
helix A, the AB loop and helix F, interacting with the IL-10
residues Glu142 and Lys138, from the IL-10 sequence
signature region, through hydrogen bonds [117]. Thus, the
main epitope observed in IL-22/IL-22R1 binary complex is
conserved in IL-10/IL-10R1.
However, when comparing the IL-10/IL-10R1 to the
IL-22/IL-22R1 site 1a interface, several differences can be
identified. The second cluster of polar residues found in the
IL-22/IL-22R1 1a interface is absent in the IL-10 binary
complex. The charged Arg73 found in IL-22 is replaced by
an apolar residue, Leu46, in the IL-10 AB loop. This
substitution impairs IL-10 interactions with the IL-10R1
loop L3 (Fig. 4).
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The IL-22R1 residues Tyr93 and Lys58 have their
structural equivalent counterparts in IL-10R1, Arg76, and
Leu41. Arg76 is found in two alternative conformations in
the IL-10/IL-10R1 crystal complex. In one of its confor-
mations, Arg76 plays the role of Tyr93 at the IL-22/IL-
22R1 interface, being hydrogen bonded to the main chain
of IL-10 Gln38 and to a water molecule. On the other hand,
the second Arg76 side chain conformation substitutes for
the IL-22R1 Lys58 side chain, making an ionic interaction
with Asp44 at IL-10 AB loop and a hydrogen bond inter-
action with Gln42 side chain. In IL-10R1, a smaller and
uncharged residue (Leu41) is at IL-22R1 Lys58 equivalent
position. Thus, the L2 loop residue Arg76, instead of the
strand C residue Lys58 (in IL-22R1), forms the ionic
interaction at the upper portion of the IL-10/IL-10R1
complex.
Another interesting feature found in the IL-10/IL-10R1
crystal complex is related to IL-10R1 L4 loop position. If
one superposes the equivalent loop region of IL-22R1 with
IL-10R1, it can be observed that the IL-10R1 loop L4 is in
a more extended conformation than the same loop in the
IL-22R1 structure. The above-mentioned WSXWS-like
motif present in IL-10R1 G strand projects its L4 loop in
the direction of IL-10. As a result, the IL-10R1 Arg96 side
chain is positioned close to the negative-charged side
chains of Asp144 and Glu142 placed on IL-10 helix F,
contributing to the binding of the interleukin to its receptor.
Furthermore, Arg96 also interacts with the IL-10 Gln38
side chain and Ser141 main chain. However, in IL-22R1,
the Arg112 side chain—that is equivalent to IL-10R1
Arg96—is positioned at the upper portion of the IL-22/IL-
22R1 site 1a due to the shorter L4 loop extension, and, as a
consequence, the interactions with IL-22 helix F are mainly
mediated by water molecules.
In the site 1b, the IL-10/IL-10R1 contacts are more
extensive than IL-22/IL22R1 crystal complex interactions.
Comparison of IL-10 and IL-22 free structures (Fig. 2)
reveals that these two interleukins display different orien-
tations of their N-terminal regions and helix A. These
features are important for receptor specificity and binding
to site 1b. In IL-10/IL-10R1 complex, the IL-10 N-terminal
portion of helix A is continuous and there are two arginine
side chains projected in the direction of the receptor (Arg24
and Arg27). These Arg side chains form a hydrogen bond
network with the main chains of Arg191 and Ser190 of the
IL-10R1 L6 loop. Furthermore, the Arg27 side chain from
site 1a
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IL-10 forms an ionic interaction with Glu151 from IL-10,
stabilizing Glu151 side chain on IL-10 helix F bent.
Therefore, Glu151 is at the ideal distance to interact with
the receptor Ser190 and Arg191 side chains (Fig. 4c) at site
1b. However, in IL-22R1 Trp208, found in the equivalent
position of IL-10R1 Arg191, makes hydrophobic contacts
with Met172 on IL-22 helix F. Furthermore, in IL-22, the
N-terminal portion of helix A is rotated, forming the preA
helix. The preA helix is extended away from the receptor,
and most of the IL-22/IL-22R1 interactions in this region
are mediated by water molecules. Similar to the IL-22/IL-
22R1 crystal complex, IL-10/IL10R1 binary complex also
contains a small hydrophobic cluster. The side chain of
Phe143, placed on IL-10R1 L5 loop, inserts itself into a
cleft formed by IL-10 Pro20 (helix A) and Ile158 (helix F),
making additional contacts in the IL-10/IL-10R1 site 1b
(Fig. 4c).
Although the binding constants of IL-10 to IL-10R1 are
in the same order of magnitude to the IL-22/IL-22R1
constants (Kd *1 nM), the IL-10/IL-10R1 complex half-
life (T1/2) is higher (T1/2 = 44 min) than the observed for
the IL-22/IL-22R1 (T1/2 = 7.4 min) [57, 157]. This is
proposed to be a consequence of the weaker contacts found
in the IL-22/IL-22R1 site 1b.
The IL-10 family members binary complexes:
structural basis of receptor specificity and promiscuity
Comparison of the IL-10/IL-10R1 and the IL-22/IL-22R1
binary complexes show conservation of the main features
of recognition between the ligand and its receptor. As
discussed above, different amino acid residues and loop
positions are observed at the two interleukin/receptor
interfaces. The maintenance of similar epitopes, conserving
the overall type and number of interactions, is possible
since both the interleukin and their receptors suffered
continuous sequence adaptations during evolution. This
guarantees receptor, and consequently, cell response
specificity to each interleukin. Besides the discrepancies
found in site 1b, the contacts found in site 1a, mainly
mediated by Tyr60 in IL-22R1 and Tyr43 in IL-10R1, are
also proposed to be a crucial determinant in interleukin/
receptor binding specificity [27, 28, 117]. The geometry of
the hydrogen bond network found in site 1a is not repro-
ducible in different interleukin/receptor pairs without
changing of their mutual orientation. Therefore, ideal
contacts at site 1a become incompatible with the simulta-
neous match at 1b interface [27] in non-cognate
interleukin/receptor pairs that in turn confers receptor
specificity.
Aiming to verify these suggestions, Jones et al. [27]
compared the AB loop sequences found in other IL-10
family members. They found that the interleukins identified
as IL-22R1 binders (IL-20 and IL-24) display structural
conserved residues with IL-22. IL-20 contains equivalent
residues at IL-22 Arg73 and Asp71 position, whereas IL-24
conserves the IL-22 Arg73 and Thr70. Accordingly, in
IL-10, IL-19 and IL-26, which do not bind IL-22R1, the
equivalent residues are absent on loop AB.
Unfortunately, the 3D structures of the IL-10s ternary
complexes are not yet available. However, site-direct
mutagenesis followed by cell-based assays and binding
studies [151, 153, 158] have generated experimental data
to propose structural models for the interleukin ternary
complex. The 3D structures of the IL-22/IL-22R1 [27, 28]
and IL-10/IL-10R1 [117] binary complexes confirm pre-
vious suggestions of the overall location of the first
receptor binding sites on IL-10 and IL-22 and also con-
tribute to a better understanding of the second receptor
interface, and hence, the overall ternary complex structure
[27, 28, 117, 153]. In the following and last section of
this review, we discuss recently published data on IL-10
members ternary complexes analysis, describing the main
interactions and binding interfaces pinpointed from these
studies.
Binary and ternary complexes models
Putative IL-10R2 binding site at the IL-22:IL-22R1 binary
complex
Several lines of evidence suggest that the IL-10R2 binding
site is located at helices A and D of IL-22 [27, 28, 151,
158]. Initially, site-directed mutagenesis and surface-plas-
mon resonance analysis revealed that IL-22 residues
(placed on helices A and D) Tyr51, Asn54, Arg55, Tyr114,
and Glu117 are important for IL-10R2 engagement with
IL-22/IL-22R1 binary complex [151]. Later, an extensive
mutagenesis study screening of 146 different IL-22 resi-
dues also included IL-22 Ile14, Thr56, Lys61, Ala66,
Val83, Arg88, Pro113, Phe121, Leu122, and Met172 as
important residues for IL-10R2 binding [158].
Very recently, based on the IL-22 binary complex
crystal structures, two independent models of IL-10R2
interaction with IL-22/IL-22R1 were proposed [27, 28].
Jones and collaborators used mutagenesis scanning analy-
sis [27] as a starting point to construct their model, whereas
Bleicher and co-workers used the recent crystal structures
of IL-4 and IL-13 ternary complexes (IL-4/cc/IL-4Ra,
IL-4/IL-13Ra1/IL-4Ra and IL-13/IL-13Ra1/IL-4Ra [159])
as an initial scaffold to model IL-10R2 interactions with
the IL-22/IL-22R1 binary complex [28]. These two inde-
pendent tertiary complex models appear to be very similar.
In both models, IL-10R2 is proposed to interact with IL-22
through two binding sites, site 2a and site 2b, that are
adjacent to the IL-22R1 sites 1a and 1b (Fig. 5a). These
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IL-10R2 binding sites are formed by IL-22 residues placed
on helices A and D, in line with alanine scanning muta-
genesis analysis [151, 158]. Furthermore, it was proposed
that IL-10R2 also contacts IL-22R1 via their respective D2
domains and the three IL-10R2 binding interfaces were
named sites 2a, 2b, and 2c [27].
Site 2a consists of putative IL-22/IL-10R2 contacts at
IL-22 C-terminal portion of helix A (Tyr51, Asn54, Arg55,
Glu63) and N-terminal portion of helix D (Tyr114). It is
important to note that Arg55 probably plays a central role
in the IL-22 binding with IL-10R2 by forming a stable
ionic interaction with IL-10R2 Asp84 on site 2a. Site 2b is
located on the helix A bent, at the terminal portion of helix
preA. In this region, a proline (Pro50) and a glutamine
(Gln48) residue are proposed to mediate interactions with,
respectively, Trp152 and Asn150 from IL-10R2 [27, 28]
(Fig. 5b). Additional residues placed nearby IL-22 helix A
bent, such as Met172, were also identified in mutagenesis
screening analysis [158] and are therefore likely to con-
tribute to IL-10R2 stabilization on site 2b. On the other
hand, site 2c is formed by residues located in the IL-22R1
and IL-10R2 D2 domains. These extra contacts promoted
by receptor/receptor interactions further contribute to the
ternary complex formation. IL-22R1 residues Glu168,
Gln176, Asn172, Thr174 and IL-10R2 Lys146, Leu132,
Arg130, Gln119, Glu121 are presumably involved in these
interactions [27, 28]. Importantly, the IL-22R1 residue
Asn174, which is presumably involved in interaction at site
2c, can be glycosylated, which in turn can also modulate
IL-22R1 contacts with IL-10R2 [27].
Small overall structural adjustments are observed when
superposing the crystal structures of free and bound IL-22
structures (IL-22/IL-22R1) (r.m.s.d. \ 0.7 A˚). However,
much more significant conformational changes are
observed at the IL-22 N-terminal region and helix A
(r.m.s.d. * 4 A˚) [28]. These structural adaptations might
result in better accommodation of IL-10R2 at the IL-22
surface (sites 2a and 2b). These conformational changes are
in concert with the notion that IL-10R2 interactions with
the IL-22R1 D2 domain contribute to the higher affinity to
the IL-22/IL-22R1 binary complex (Kd = 14 lM) than to
IL-22 alone (Kd = 120 lM) [27, 151].
Putative IL-10R2 binding site at the IL-10:IL-10R1 binary
complex
Overall, the IL-10R2 interactions with the IL-10/IL-10R1
binary complex are likely to be similar to those proposed for
the IL-22/IL-22R1/IL-10R2 ternary complex. However,
structural differences on the molecular level must explain
the higher affinity displayed by IL-10R2 when binding to
IL-22 (Kd = 120 lM (free IL-22) and Kd = 14 lM (IL-22/
IL-22R1 [151]) in comparison to IL-10 (Kd * 1 mM (free
IL-10) and Kd = 234 lM (IL-10/IL-10R1) [153]).
According to the proposed IL-10 and IL-22 ternary
complexes, it has been argued that the flatter IL-10 helix A
site 2b
site 1b
site 2a
site 1a
A
preA
D
loop AB
F1
F2
site 2a 
site 2b
M22
N21
R24 P50
Q48
E62
Y114
R55
N54
Y51
S31
R32
S93
H90
A
B
Fig. 5 IL-22 ternary complex
interfaces. a IL-22R1 and
putative IL-10R2 interfaces
mapped on the IL-22 surface
(PDB ID 2M4R [8]). Site 1a is
colored orange, site 1b red, site
2a cyan, and site 2b blue.
b Detailed view of the potential
IL-10R2 binding interfaces at
IL-10 (PDB ID 2YLK [130];
colored green) and IL-22 (PDB
ID 2M4R [8]; colored light
grey) crystal structures. Oxygen
atoms are shown in red and
nitrogen in blue. Figures were
generated with PyMOL
software (DeLano Scientific)
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is the main cause for weakening the IL-10R2 contacts with
IL-10 on site 2a and 2b [27]. In IL-22, Tyr51 stabilizes and
orients Arg55 that forms an ionic interaction with Asp84
from IL-10R2 on site 2a. In contrast, in IL-10, the Arg32
residue (which plays the role of Arg55 in IL-22) is not
stabilized by any additional interactions. Furthermore,
IL-10 Arg32 is one turn of a helix away from IL-22 Arg55
(Fig. 5b), and its side chain must be reoriented to interact
with IL-10R2 Asp84. Therefore, it is proposed that this salt
bridge is weakened in IL-10/IL-10R2 site 2a, and might be
one of the main reasons for the low free IL-10 affinity to
IL-10R2 [27].
Conformational changes at the IL-10 N-terminal portion
of helix A are observed when comparing free and IL-10R1
bound IL-10 crystal structures. Residues 18–22 suffer a
rigid body movement ([5 A˚) produced by rotating (26)
Leu23 phi\psi angles. As a result, in the receptor-bound
IL-10, helix A is longer and straighter than in free IL-10.
These conformational changes are proposed to be essential
for IL-10R2 binding to IL-10 [153] and corroborate with
the experimental IL-10R2 binding affinities to free and
bound IL-10.
The IL-10R2 binding interface was investigated by
different methodologies [27, 117, 151, 153]. Based on
IL-10 binary complex crystal structure [117] and on
previous IL-22 mutagenesis analysis [151], Yoon and
co-workers (2006) [153] designed IL-10 alanine mutants
to search for the potential IL-10R2 binding site on this
interleukin. They found that, similar to IL-22, IL-10
residues placed on the C-terminal portion of helix A
(Ser31 and Arg32) and residues from helix D (His90 and
Ser93) are involved in site 2a contacts with IL-10R2,
whereas, the N-terminal portion of helix A (Asn21,
Met22, and Arg24) is involved in contacts related to site
2b. Additionally, structural modeling of IL-10R2 on
IL-10/IL-10R1 binary complex [27] revealed that, as
observed to IL-22, IL-10R2 can also contact IL-10R1
through interactions with their D2 domains, thus forming
site 2c, which further contributes to IL-10 ternary com-
plex stabilization.
Although the overall IL-10R2 binding interfaces at the
IL-22 and IL-10 ternary complexes are similar, the
molecular details are quite different [160]. It appears that
site 2b is the most important IL-10R2 interface in IL-10
ternary complex; whereas site 2a is central for IL-22
ternary complex formation [153]. IL-10 Met22 seems to
play a primary role in IL-10R2 binding, by helping the
rigidification of IL-10 N-terminal region and by inter-
acting directly with IL-10R2 through hydrophobic
interactions. Furthermore, Arg24, which also participates
in IL-10/IL-10R1 site 1b interactions, is probably
involved in polar contacts with IL-10R2 L5 loop on site
2b [153].
Putative IL-19, IL-20, and IL-24 binary and ternary
complexes: structural models
Unfortunately, the crystal structures of IL-19 or IL-20
complexes with receptors are currently not available, and
neither are IL-20R1 nor IL-20R2 structures. However, due
to IL-19 structural similarities with IL-10, Chang et al. [24]
generated a model describing the potential hot-spots in
IL-19, based on the IL-10/IL-10R1 crystal structure [117].
One year later, in 2004, Preimeland and Sticht [161, 162]
also proposed a model for IL-20R1 interaction with IL-19,
using the IFN-c binary complex crystal structure as a
starting model [163]. In both hypothetical 3D structures,
IL-19 AB loop interacts with IL-20R1 loops, in a similar
mode to the one observed for IL-10, with contributions
from IL-19 helices A and F [24, 161]. Chang and
co-workers found that superposition of IL-19 with IL-10 in
the IL-10/IL-10R1 binary complex shows that the majority
of the interactions found in IL-10/IL-10R1 site 1a and 1b
are allowed [24]. However, a clash between IL-10R1
Glu46 and the glycosylated IL-19 Asn38 is observed.
Comparisons of this model with IL-20 and IL-24 amino
acid sequences (which also bind to IL-20R1) indicate that
the IL-20R1 interaction sites are probably conserved in
these two interleukins [161]. Along the same lines, the
predicted IL-20R2 binding sites to IL-19 are similar to
IL-10R2 binding site to IL-10. Thus, the possible IL-19
receptor binding sites are probably located at the IL-19
helix A, loop AB, helices D and F, and at its C-terminal
portion [24].
Differently from IL-10 and IL-22, experimental evi-
dence suggests that IL-19 and IL-20 display high affinity to
IL-20R2, and that IL-20R1 binding occurs after the binary
complex formation with the short-chain receptor (IL-20R2)
[68, 72]. However, the molecular basis of these events is
currently unknown.
Putative IFN-k3 residues involved in binary and ternary
complex formation: site-direct mutagenesis analysis
Based on the known IL-10/IL-10R1 and IL-22/IL-22R1
binary complexes 3D structures, on the putative IL-10R2
interfaces and on the recent IFN-k3 crystal structure, Gad
and co-workers designed IFN-k3 Ala mutants to pinpoint
binding hotspots [23]. They found that the interface related
to site 1b of IL-10 and IL-22 plays the major role in
IFN-k3/IFN-kR1 interactions. In IFN-k3, the polar residues
positioned at IFN-k3 helix A (Arg33, Arg34, Lys36, and
Asp37) and hydrophobic residues of the helix F (Phe155
and Phe158) are the most sensitive for Ala mutations.
Furthermore, IFN-k3 mutants were constructed to shed
light on the putative IFN-k3/IFN-kR1/IL-10R2 interface.
Residues at IFN-k3 helix D (at the vicinity of Gln100) were
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shown to be essential for IL-10R2 binding. Moreover, the
IFN-kR1 and IL-10R2 interfaces are probably placed at
IFN-k3 helix A [23].
Considerations about IL-26 binary and ternary complexes
Experimental evidence suggests that IL-26, differently
from IL-19, IL-20 and IL-24, uses IL-20R1 and IL-10R2
for signaling. It is interesting to note that IL-26 is the only
IL-10 family member that employs this pair of receptors in
its function [13, 138–140]. However, little experimental
data is currently available concerning crystal structures of
IL-26 and its complexes with the cognate receptors.
Therefore, at this point, it would be far too speculative to
argue about binary and ternary complexes of IL-26 and
atomic details of its interactions with the cognate IL-20R1
and IL-10R2 receptors.
References
1. Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A (2001)
Interleukin-10 and the interleukin-10 receptor. Annu Rev
Immunol 19:683–765
2. Gallagher G, Dickensheets H, Eskdale J, Izotova LS, Mir-
ochnitchenko OV, Peat JD, Vazquez N, Pestka S, Donnelly RP,
Kotenko SV (2000) Cloning, expression and initial character-
ization of interleukin-19 (IL-19), a novel homologue of human
interleukin-10 (IL-10). Genes Immun 1:442–450
3. Dumoutier L, Renauld JC (2002) Viral and cellular interleukin-
10 (IL-10)-related cytokines: from structures to functions. Eur
Cytokine Netw 13:5–15
4. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer
S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J,
Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B,
Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W,
McKnight G, Clegg C, Foster D, Klucher KM (2003) IL-28,
IL-29 and their class II cytokine receptor IL-28R. Nat Immunol
4:63–68
5. Kotenko SV (2002) The family of IL-10-related cytokines and
their receptors: related, but to what extent? Cytokine Growth
Factor Rev 13:223–240
6. Walter MR, Nagabhushan TL (1995) Crystal structure of
interleukin-10 reveals an interferon gamma-like fold. Bio-
chemistry 34:12118–12125
7. Zdanov A, Schalk-Hihi C, Gustchina A, Tsang M, Weatherbee
J, Wlodawer A (1995) Crystal structure of interleukin-10 reveals
the functional dimer with an unexpected topological similarity
to interferon gamma. Structure 3:591–601
8. Nagem RA, Colau D, Dumoutier L, Renauld JC, Ogata C,
Polikarpov I (2002) Crystal structure of recombinant human
interleukin-22. Structure 10:1051–1062
9. Wolk K, Kunz S, Asadullah K, Sabat R (2002) Cutting edge:
immune cells as sources and targets of the IL-10 family mem-
bers? J Immunol 168:5397–5402
10. Dumoutier L, Leemans C, Lejeune D, Kotenko SV, Renauld JC
(2001) Cutting edge: STAT activation by IL-19, IL-20 and mda-
7 through IL-20 receptor complexes of two types. J Immunol
167:3545–3549
11. Liu Y, Wei SH, Ho AS, de Waal Malefyt R, Moore KW (1994)
Expression cloning and characterization of a human IL-10
receptor. J Immunol 152:1821–1829
12. Kotenko SV, Krause CD, Izotova LS, Pollack BP, Wu W, Pestka
S (1997) Identification and functional characterization of a
second chain of the interleukin-10 receptor complex. EMBO J
16:5894–5903
13. Zdanov A (2006) Structural studies of the interleukin-19 sub-
family of cytokines. Vitam Horm 74:61–76
14. Renauld JC (2003) Class II cytokine receptors and their ligands:
key antiviral and inflammatory modulators. Nat Rev Immunol
3:667–676
15. Griffiths CE, Barker JN (2007) Pathogenesis and clinical fea-
tures of psoriasis. Lancet 370:263–271
16. Wolk K, Witte E, Wallace E, Docke WD, Kunz S, Asadullah K,
Volk HD, Sterry W, Sabat R (2006) IL-22 regulates the
expression of genes responsible for antimicrobial defense, cel-
lular differentiation, and mobility in keratinocytes: a potential
role in psoriasis. Eur J Immunol 36:1309–1323
17. Wolk K, Haugen HS, Xu W, Witte E, Waggie K, Anderson M,
Vom Baur E, Witte K, Warszawska K, Philipp S, Johnson-Leger
C, Volk HD, Sterry W, Sabat R (2009) IL-22 and IL-20 are key
mediators of the epidermal alterations in psoriasis while IL-17
and IFN-gamma are not. J Mol Med 87:523–536
18. Choy EH, Panayi GS (2001) Cytokine pathways and joint
inflammation in rheumatoid arthritis. N Engl J Med 344:907–
916
19. Ikeuchi H, Kuroiwa T, Hiramatsu N, Kaneko Y, Hiromura K,
Ueki K, Nojima Y (2005) Expression of interleukin-22 in
rheumatoid arthritis: potential role as a proinflammatory cyto-
kine. Arthritis Rheum 52:1037–1046
20. Geboes L, Dumoutier L, Kelchtermans H, Schurgers E, Mitera
T, Renauld JC, Matthys P (2009) Proinflammatory role of the
Th17 cytokine interleukin-22 in collagen-induced arthritis in
C57BL/6 mice. Arthritis Rheum 60:390–395
21. Martinez JA, King TE Jr, Brown K, Jennings CA, Borish L,
Mortenson RL, Khan TZ, Bost TW, Riches DW (1997)
Increased expression of the interleukin-10 gene by alveolar
macrophages in interstitial lung disease. Am J Physiol
273:L676–L683
22. Whittington HA, Armstrong L, Uppington KM, Millar AB
(2004) Interleukin-22: a potential immunomodulatory molecule
in the lung. Am J Respir Cell Mol Biol 31:220–226
23. Gad HH, Dellgren C, Hamming OJ, Vends S, Paludan SR,
Hartmann R (2009) Interferon-k is functionally an interferon but
structurally related to the interleukin-10 family. J Biol Chem
284:20869–20875
24. Chang C, Magracheva E, Kozlov S, Fong S, Tobin G, Kotenko
S, Wlodawer A, Zdanov A (2003) Crystal structure of inter-
leukin-19 defines a new subfamily of helical cytokines. J Biol
Chem 278:3308–3313
25. Xu T, Logsdon NJ, Walter MR (2005) Structure of insect-cell-
derived IL-22. Acta Crystallogr D Biol Crystallogr 61:942–950
26. Nagem RA, Ferreira Junior JR, Dumoutier L, Renauld JC,
Polikarpov I (2006) Interleukin-22 and its crystal structure.
Vitam Horm 74:77–103
27. Jones BC, Logsdon NJ, Walter MR (2008) Structure of IL-22
bound to its high-affinity IL-22R1 chain. Structure 16:1333–
1344
28. Bleicher L, de Moura PR, Watanabe L, Colau D, Dumoutier L,
Renauld JC, Polikarpov I (2008) Crystal structure of the IL-22/
IL-22R1 complex and its implications for the IL-22 signaling
mechanism. FEBS Lett 582:2985–2992
29. Zdanov A (2004) Structural features of the interleukin-10 family
of cytokines. Curr Pharm Des 10:3873–3884
2930 D. B. B. Trivella et al.
30. Dumoutier L, Louahed J, Renauld JC (2000) Cloning and
characterization of IL-10-related T cell-derived inducible factor
(IL-TIF), a novel cytokine structurally related to IL-10 and
inducible by IL-9. J Immunol 164:1814–1819
31. Dumoutier L, Van Roost E, Ameye G, Michaux L, Renauld JC
(2000) IL-TIF/IL-22: genomic organization and mapping of the
human and mouse genes. Genes Immun 1:488–494
32. Dumoutier L, Van Roost E, Colau D, Renauld JC (2000) Human
interleukin-10-related T cell-derived inducible factor: molecular
cloning and functional characterization as an hepatocyte-stim-
ulating factor. Proc Natl Acad Sci USA 97:10144–10149
33. Aggarwal S, Xie MH, Maruoka M, Foster J, Gurney AL (2001)
Acinar cells of the pancreas are a target of interleukin-22.
J Interferon Cytokine Res 21:1047–1053
34. Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joan-
nopoulos K, Collins M, Fouser LA (2006) Interleukin (IL)-22
and IL-17 are coexpressed by Th17 cells and cooperatively
enhance expression of antimicrobial peptides. J Exp Med
203:2271–2279
35. Boniface K, Bernard FX, Garcia M, Gurney AL, Lecron JC,
Morel F (2005) IL-22 inhibits epidermal differentiation and
induces proinflammatory gene expression and migration of
human keratinocytes. J Immunol 174:3695–3702
36. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL,
Murphy KM, Weaver CT (2005) Interleukin 17-producing
CD4? effector T cells develop via a lineage distinct from the T
helper type 1 and 2 lineages. Nat Immunol 6:1123–1132
37. Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R
(2004) IL-22 increases the innate immunity of tissues. Immunity
21:241–254
38. Lehrer RI, Ganz T (2002) Defensins of vertebrate animals. Curr
Opin Immunol 14:96–102
39. Zasloff M (2002) Antimicrobial peptides of multicellular
organisms. Nature 415:389–395
40. Boniface K, Guignouard E, Pedretti N, Garcia M, Delwail A,
Bernard FX, Nau F, Guillet G, Dagregorio G, Yssel H, Lecron
JC, Morel F (2007) A role for T cell-derived interleukin 22 in
psoriatic skin inflammation. Clin Exp Immunol 150:407–415
41. Ma HL, Liang S, Li J, Napierata L, Brown T, Benoit S, Senices
M, Gill D, Dunussi-Joannopoulos K, Collins M, Nickerson-
Nutter C, Fouser LA, Young DA (2008) IL-22 is required for
Th17 cell-mediated pathology in a mouse model of psoriasis-
like skin inflammation. J Clin Invest 118:597–607
42. Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-
Anderson J, Wu J, Ouyang W (2007) Interleukin-22, a T(H)17
cytokine, mediates IL-23-induced dermal inflammation and
acanthosis. Nature 445:648–651
43. Zheng B, Switzer K, Marinova E, Zhang J, Han S (2008)
Exacerbation of autoimmune arthritis by copolymer-I through
promoting type 1 immune response and autoantibody produc-
tion. Autoimmunity 41:363–371
44. Sugimoto K, Ogawa A, Mizoguchi E, Shimomura Y, Andoh A,
Bhan AK, Blumberg RS, Xavier RJ, Mizoguchi A (2008) IL-22
ameliorates intestinal inflammation in a mouse model of ulcer-
ative colitis. J Clin Invest 118:534–544
45. Aujla SJ, Chan YR, Zheng M, Fei M, Askew DJ, Pociask DA,
Reinhart TA, McAllister F, Edeal J, Gaus K, Husain S, Krein-
dler JL, Dubin PJ, Pilewski JM, Myerburg MM, Mason CA,
Iwakura Y, Kolls JK (2008) IL-22 mediates mucosal host
defense against Gram-negative bacterial pneumonia. Nat Med
14:275–281
46. Pickert G, Neufert C, Leppkes M, Zheng Y, Wittkopf N,
Warntjen M, Lehr HA, Hirth S, Weigmann B, Wirtz S, Ouyang
W, Neurath MF, Becker C (2009) STAT3 links IL-22 signaling
in intestinal epithelial cells to mucosal wound healing. J Exp
Med 206:1465–1472
47. Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ,
Stevens S, Flavell RA (2008) Innate and adaptive interleukin-22
protects mice from inflammatory bowel disease. Immunity
29:947–957
48. Pan H, Hong F, Radaeva S, Gao B (2004) Hydrodynamic gene
delivery of interleukin-22 protects the mouse liver from con-
canavalin A-, carbon tetrachloride-, and Fas ligand-induced
injury via activation of STAT3. Cell Mol Immunol 1:43–49
49. Radaeva S, Sun R, Pan HN, Hong F, Gao B (2004) Interleukin
22 (IL-22) plays a protective role in T cell-mediated murine
hepatitis: IL-22 is a survival factor for hepatocytes via STAT3
activation. Hepatology 39:1332–1342
50. Wolk K, Sabat R (2006) Interleukin-22: a novel T- and NK-cell
derived cytokine that regulates the biology of tissue cells.
Cytokine Growth Factor Rev 17:367–380
51. Luci C, Reynders A, Ivanov II, Cognet C, Chiche L, Chasson L,
Hardwigsen J, Anguiano E, Banchereau J, Chaussabel D, Dalod
M, Littman DR, Vivier E, Tomasello E (2009) Influence of the
transcription factor RORgammat on the development
of NKp46? cell populations in gut and skin. Nat Immunol
10:75–82
52. Sanos SL, Bui VL, Mortha A, Oberle K, Heners C, Johner C,
Diefenbach A (2009) RORgammat and commensal microflora
are required for the differentiation of mucosal interleukin
22-producing NKp46? cells. Nat Immunol 10:83–91
53. Satoh-Takayama N, Vosshenrich CA, Lesjean-Pottier S, Sawa
S, Lochner M, Rattis F, Mention JJ, Thiam K, Cerf-Bensussan
N, Mandelboim O, Eberl G, Di Santo JP (2008) Microbial flora
drives interleukin 22 production in intestinal NKp46? cells that
provide innate mucosal immune defense. Immunity 29:958–970
54. Cella M, Fuchs A, Vermi W, Facchetti F, Otero K, Lennerz JK,
Doherty JM, Mills JC, Colonna M (2009) A human natural killer
cell subset provides an innate source of IL-22 for mucosal
immunity. Nature 457:722–725
55. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB
(2004) Interleukin-10 and related cytokines and receptors. Annu
Rev Immunol 22:929–979
56. Xu T, Logsdon NJ, Walter MR (2004) Crystallization and X-ray
diffraction analysis of insect-cell-derived IL-22. Acta Crystal-
logr D Biol Crystallogr 60:1295–1298
57. Logsdon NJ, Jones BC, Josephson K, Cook J, Walter MR (2002)
Comparison of interleukin-22 and interleukin-10 soluble
receptor complexes. J Interferon Cytokine Res 22:1099–1112
58. de Oliveira Neto M, Ferreira JR Jr, Colau D, Fischer H,
Nascimento AS, Craievich AF, Dumoutier L, Renauld JC,
Polikarpov I (2008) Interleukin-22 forms dimers that are rec-
ognized by two interleukin-22R1 receptor chains. Biophys J
94:1754–1765
59. Loiarro M, Sette C, Gallo G, Ciacci A, Fanto N, Mastroianni D,
Carminati P, Ruggiero V (2005) Peptide-mediated interference
of TIR domain dimerization in MyD88 inhibits interleukin-1-
dependent activation of NF-kappa B. J Biol Chem 280:15809–
15814
60. Stuhlmann-Laeisz C, Lang S, Chalaris A, Krzysztof P, Enge S,
Eichler J, Klingmuller U, Samuel M, Ernst M, Rose-John S,
Scheller J (2006) Forced dimerization of gp130 leads to con-
stitutive STAT3 activation, cytokine-independent growth, and
blockade of differentiation of embryonic stem cells. Mol Biol
Cell 17:2986–2995
61. Liao YC, Liang WG, Chen FW, Hsu JH, Yang JJ, Chang MS
(2002) IL-19 induces production of IL-6 and TNF-alpha and
results in cell apoptosis through TNF-alpha. J Immunol
169:4288–4297
62. Parrish-Novak J, Xu W, Brender T, Yao L, Jones C, West J,
Brandt C, Jelinek L, Madden K, McKernan PA, Foster DC,
Jaspers S, Chandrasekher YA (2002) Interleukins 19, 20, and 24
Structure and function of interleukin-10 family 2931
signal through two distinct receptor complexes. Differences in
receptor-ligand interactions mediate unique biological functions.
J Biol Chem 277:47517–47523
63. Jordan WJ, Eskdale J, Boniotto M, Lennon GP, Peat J, Campbell
JD, Gallagher G (2005) Human IL-19 regulates immunity
through auto-induction of IL-19 and production of IL-10. Eur J
Immunol 35:1576–1582
64. Gallagher G, Eskdale J, Jordan W, Peat J, Campbell J, Boniotto
M, Lennon GP, Dickensheets H, Donnelly RP (2004) Human
interleukin-19 and its receptor: a potential role in the induction
of Th2 responses. Int Immunopharmacol 4:615–626
65. Liao SC, Cheng YC, Wang YC, Wang CW, Yang SM, Yu CK,
Shieh CC, Cheng KC, Lee MF, Chiang SR, Shieh JM, Chang
MS (2004) IL-19 induced Th2 cytokines and was up-regulated
in asthma patients. J Immunol 173:6712–6718
66. Tian Y, Sommerville LJ, Cuneo A, Kelemen SE, Autieri MV
(2008) Expression and suppressive effects of interleukin-19 on
vascular smooth muscle cell pathophysiology and development
of intimal hyperplasia. Am J Pathol 173:901–909
67. Romer J, Hasselager E, Norby PL, Steiniche T, Thorn Clausen J,
Kragballe K (2003) Epidermal overexpression of interleukin-19
and -20 mRNA in psoriatic skin disappears after short-term
treatment with cyclosporine a or calcipotriol. J Invest Dermatol
121:1306–1311
68. Blumberg H, Conklin D, Xu WF, Grossmann A, Brender T,
Carollo S, Eagan M, Foster D, Haldeman BA, Hammond A,
Haugen H, Jelinek L, Kelly JD, Madden K, Maurer MF, Parrish-
Novak J, Prunkard D, Sexson S, Sprecher C, Waggie K, West J,
Whitmore TE, Yao L, Kuechle MK, Dale BA, Chandrasekher
YA (2001) Interleukin 20: discovery, receptor identification, and
role in epidermal function. Cell 104:9–19
69. Wolk K, Witte K, Witte E, Proesch S, Schulze-Tanzil G,
Nasilowska K, Thilo J, Asadullah K, Sterry W, Volk HD, Sabat
R (2008) Maturing dendritic cells are an important source of
IL-29 and IL-20 that may cooperatively increase the innate
immunity of keratinocytes. J Leukoc Biol 83:1181–1193
70. Hosoi T, Wada S, Suzuki S, Okuma Y, Akira S, Matsuda T,
Nomura Y (2004) Bacterial endotoxin induces IL-20 expression
in the glial cells. Brain Res Mol Brain Res 130:23–29
71. Hsing CH, Ho CL, Chang LY, Lee YL, Chuang SS, Chang MS
(2006) Tissue microarray analysis of interleukin-20 expression.
Cytokine 35:44–52
72. Pletnev S, Magracheva E, Kozlov S, Tobin G, Kotenko SV,
Wlodawer A, Zdanov A (2003) Characterization of the recom-
binant extracellular domains of human interleukin-20 receptors
and their complexes with interleukin-19 and interleukin-20.
Biochemistry 42:12617–12624
73. Jiang H, Lin JJ, Su ZZ, Goldstein NI, Fisher PB (1995) Sub-
traction hybridization identifies a novel melanoma
differentiation associated gene, mda-7, modulated during human
melanoma differentiation, growth and progression. Oncogene
11:2477–2486
74. Barton K, Randall G, Sagone AL Jr (1989) The effects of the
anti-tumor agent mezerein on the cytotoxic capacity and oxi-
dative metabolism of human blood cells. Invest New Drugs
7:179–188
75. Fisher PB, Prignoli DR, Hermo H Jr, Weinstein IB, Pestka S
(1985) Effects of combined treatment with interferon and
mezerein on melanogenesis and growth in human melanoma
cells. J Interferon Res 5:11–22
76. Fisher PB (2005) Is mda-7/IL-24 a ‘‘magic bullet’’ for cancer?
Cancer Res 65:10128–10138
77. Fisher PB, Gopalkrishnan RV, Chada S, Ramesh R, Grimm EA,
Rosenfeld MR, Curiel DT, Dent P (2003) mda-7/IL-24, a novel
cancer selective apoptosis inducing cytokine gene: from the
laboratory into the clinic. Cancer Biol Ther 2:S23–S37
78. Lebedeva IV, Sauane M, Gopalkrishnan RV, Sarkar D, Su ZZ,
Gupta P, Nemunaitis J, Cunningham C, Yacoub A, Dent P,
Fisher PB (2005) mda-7/IL-24: exploiting cancer’s Achilles’
heel. Mol Ther 11:4–18
79. Sauane M, Gopalkrishnan RV, Sarkar D, Su ZZ, Lebedeva IV,
Dent P, Pestka S, Fisher PB (2003) MDA-7/IL-24: novel cancer
growth suppressing and apoptosis inducing cytokine. Cytokine
Growth Factor Rev 14:35–51
80. Huang EY, Madireddi MT, Gopalkrishnan RV, Leszczyniecka
M, Su Z, Lebedeva IV, Kang D, Jiang H, Lin JJ, Alexandre D,
Chen Y, Vozhilla N, Mei MX, Christiansen KA, Sivo F,
Goldstein NI, Mhashilkar AB, Chada S, Huberman E, Pestka S,
Fisher PB (2001) Genomic structure, chromosomal localization
and expression profile of a novel melanoma differentiation
associated (mda-7) gene with cancer specific growth suppressing
and apoptosis inducing properties. Oncogene 20:7051–7063
81. Schaefer G, Venkataraman C, Schindler U (2001) Cutting edge:
FISP (IL-4-induced secreted protein), a novel cytokine-like
molecule secreted by Th2 cells. J Immunol 166:5859–5863
82. Soo C, Shaw WW, Freymiller E, Longaker MT, Bertolami CN,
Chiu R, Tieu A, Ting K (1999) Cutaneous rat wounds express
c49a, a novel gene with homology to the human melanoma
differentiation associated gene, mda-7. J Cell Biochem 74:1–10
83. Wang M, Tan Z, Zhang R, Kotenko SV, Liang P (2002) Inter-
leukin 24 (MDA-7/MOB-5) signals through two heterodimeric
receptors, IL-22R1/IL-20R2 and IL-20R1/IL-20R2. J Biol Chem
277:7341–7347
84. He M, Liang P (2010) IL-24 transgenic mice: in vivo evidence
of overlapping functions for IL-20, IL-22, and IL-24 in the
epidermis. J Immunol 184:1793–1798
85. Kreis S, Philippidou D, Margue C, Behrmann I (2008) IL-24: a
classic cytokine and/or a potential cure for cancer? J Cell Mol
Med 12:2505–2510
86. Sauane M, Lebedeva IV, Su ZZ, Choo HT, Randolph A, Valerie
K, Dent P, Gopalkrishnan RV, Fisher PB (2004) Melanoma
differentiation associated gene-7/interleukin-24 promotes tumor
cell-specific apoptosis through both secretory and nonsecretory
pathways. Cancer Res 64:2988–2993
87. Breckenridge DG, Germain M, Mathai JP, Nguyen M, Shore GC
(2003) Regulation of apoptosis by endoplasmic reticulum
pathways. Oncogene 22:8608–8618
88. Pahl HL (1999) Signal transduction from the endoplasmic
reticulum to the cell nucleus. Physiol Rev 79:683–701
89. Cunningham CC, Chada S, Merritt JA, Tong A, Senzer N,
Zhang Y, Mhashilkar A, Parker K, Vukelja S, Richards D, Hood
J, Coffee K, Nemunaitis J (2005) Clinical and local biological
effects of an intratumoral injection of mda-7 (IL24; INGN 241)
in patients with advanced carcinoma: a phase I study. Mol Ther
11:149–159
90. Tong AW, Nemunaitis J, Su D, Zhang Y, Cunningham C,
Senzer N, Netto G, Rich D, Mhashilkar A, Parker K, Coffee K,
Ramesh R, Ekmekcioglu S, Grimm EA, van Wart Hood J,
Merritt J, Chada S (2005) Intratumoral injection of INGN 241, a
nonreplicating adenovector expressing the melanoma-differen-
tiation associated gene-7 (mda-7/IL24): biologic outcome in
advanced cancer patients. Mol Ther 11:160–172
91. Ramesh R, Mhashilkar AM, Tanaka F, Saito Y, Branch CD,
Sieger K, Mumm JB, Stewart AL, Boquoi A, Dumoutier L,
Grimm EA, Renauld JC, Kotenko S, Chada S (2003) Melanoma
differentiation-associated gene 7/interleukin (IL)-24 is a novel
ligand that regulates angiogenesis via the IL-22 receptor. Cancer
Res 63:5105–5113
92. Inoue S, Branch CD, Gallick GE, Chada S, Ramesh R (2005)
Inhibition of Src kinase activity by Ad-mda7 suppresses vas-
cular endothelial growth factor expression in prostate carcinoma
cells. Mol Ther 12:707–715
2932 D. B. B. Trivella et al.
93. Caudell EG, Mumm JB, Poindexter N, Ekmekcioglu S,
Mhashilkar AM, Yang XH, Retter MW, Hill P, Chada S, Grimm
EA (2002) The protein product of the tumor suppressor gene,
melanoma differentiation-associated gene 7, exhibits immuno-
stimulatory activity and is designated IL-24. J Immunol
168:6041–6046
94. Maarof G, Bouchet-Delbos L, Gary-Gouy H, Durand-Gasselin I,
Krzysiek R, Dalloul A (2010) Interleukin-24 inhibits the plasma
cell differentiation program in human germinal center B cells.
Blood 115:1718–1726
95. Jones BC, Logsdon NJ, Josephson K, Cook J, Barry PA, Walter
MR (2002) Crystal structure of human cytomegalovirus IL-10
bound to soluble human IL-10R1. Proc Natl Acad Sci USA
99:9404–9409
96. Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko
SV, Renauld JC (2004) Role of the interleukin (IL)-28 receptor
tyrosine residues for antiviral and antiproliferative activity of
IL-29/interferon-lambda 1: similarities with type I interferon
signaling. J Biol Chem 279:32269–32274
97. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M,
Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP
(2003) IFN-lambdas mediate antiviral protection through a
distinct class II cytokine receptor complex. Nat Immunol
4:69–77
98. Zitzmann K, Brand S, Baehs S, Goke B, Meinecke J, Spottl G,
Meyer H, Auernhammer CJ (2006) Novel interferon-lambdas
induce antiproliferative effects in neuroendocrine tumor cells.
Biochem Biophys Res Commun 344:1334–1341
99. Numasaki M, Tagawa M, Iwata F, Suzuki T, Nakamura A,
Okada M, Iwakura Y, Aiba S, Yamaya M (2007) IL-28 elicits
antitumor responses against murine fibrosarcoma. J Immunol
178:5086–5098
100. Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T (2006)
Antitumor activity of IFN-lambda in murine tumor models.
J Immunol 176:7686–7694
101. Li M, Liu X, Zhou Y, Su SB (2009) Interferon-lambdas: the
modulators of antivirus, antitumor, and immune responses.
J Leukoc Biol 86:23–32
102. Maher SG, Sheikh F, Scarzello AJ, Romero-Weaver AL, Baker
DP, Donnelly RP, Gamero AM (2008) IFNalpha and IFNlambda
differ in their antiproliferative effects and duration of JAK/
STAT signaling activity. Cancer Biol Ther 7:1109–1115
103. Meager A, Visvalingam K, Dilger P, Bryan D, Wadhwa M
(2005) Biological activity of interleukins-28 and -29: compari-
son with type I interferons. Cytokine 31:109–118
104. Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler
R, Storey H, Yao L, Liu H, Barahmand-pour F, Sivakumar P,
Chan C, Birks C, Foster D, Clegg CH, Wietzke-Braun P, Mihm
S, Klucher KM (2006) Interleukin-29 uses a type 1 interferon-
like program to promote antiviral responses in human hepato-
cytes. Hepatology 44:896–906
105. Donnelly RP, Sheikh F, Kotenko SV, Dickensheets H (2004)
The expanded family of class II cytokines that share the IL-10
receptor-2 (IL-10R2) chain. J Leukoc Biol 76:314–321
106. Sommereyns C, Paul S, Staeheli P, Michiels T (2008) IFN-
lambda (IFN-lambda) is expressed in a tissue-dependent fashion
and primarily acts on epithelial cells in vivo. PLoS Pathog
4:e1000017
107. Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte
JM, Diebold J, Diepolder H, Adler B, Auernhammer CJ, Goke
B, Dambacher J (2005) IL-28A and IL-29 mediate antiprolif-
erative and antiviral signals in intestinal epithelial cells and
murine CMV infection increases colonic IL-28A expression.
Am J Physiol Gastrointest Liver Physiol 289:G960–G968
108. Mordstein M, Kochs G, Dumoutier L, Renauld JC, Paludan SR,
Klucher K, Staeheli P (2008) Interferon-lambda contributes to
innate immunity of mice against influenza A virus but not
against hepatotropic viruses. PLoS Pathog 4:e1000151
109. Plockinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de
Herder WW, Goede A, Caplin M, Oberg K, Reubi JC, Nilsson
O, Delle Fave G, Ruszniewski P, Ahlman H, Wiedenmann B
(2004) Guidelines for the diagnosis and treatment of neuroen-
docrine gastrointestinal tumours. A consensus statement on
behalf of the European Neuroendocrine Tumour Society
(ENETS). Neuroendocrinology 80:394–424
110. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban
TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M,
McHutchison JG, Goldstein DB (2009) Genetic variation in
IL28B predicts hepatitis C treatment-induced viral clearance.
Nature 461:399–401
111. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C,
Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD,
Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison
JG, Goldstein DB, Carrington M (2009) Genetic variation in
IL28B and spontaneous clearance of hepatitis C virus. Nature
461:798–801
112. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M,
Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E,
Riordan S, Sheridan D, Smedile A, Fragomeli V, Muller T,
Bahlo M, Stewart GJ, Booth DR, George J (2009) IL28B is
associated with response to chronic hepatitis C interferon-alpha
and ribavirin therapy. Nat Genet 41:1100–1104
113. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K,
Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y,
Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A,
Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K,
Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizo-
kami M (2009) Genome-wide association of IL28B with
response to pegylated interferon-alpha and ribavirin therapy for
chronic hepatitis C. Nat Genet 41:1105–1109
114. Pagliaccetti NE, Eduardo R, Kleinstein SH, Mu XJ, Bandi P,
Robek MD (2008) Interleukin-29 functions cooperatively with
interferon to induce antiviral gene expression and inhibit hepa-
titis C virus replication. J Biol Chem 283:30079–30089
115. Fiorentino DF, Bond MW, Mosmann TR (1989) Two types of
mouse T helper cell. IV. Th2 clones secrete a factor that inhibits
cytokine production by Th1 clones. J Exp Med 170:2081–2095
116. O’Garra A, Vieira P (2007) T(H)1 cells control themselves by
producing interleukin-10. Nat Rev Immunol 7:425–428
117. Josephson K, Logsdon NJ, Walter MR (2001) Crystal structure
of the IL-10/IL-10R1 complex reveals a shared receptor binding
site. Immunity 15:35–46
118. Riley JK, Takeda K, Akira S, Schreiber RD (1999) Interleukin-
10 receptor signaling through the JAK-STAT pathway.
Requirement for two distinct receptor-derived signals for anti-
inflammatory action. J Biol Chem 274:16513–16521
119. Jenkins JK, Malyak M, Arend WP (1994) The effects of inter-
leukin-10 on interleukin-1 receptor antagonist and interleukin-1
beta production in human monocytes and neutrophils. Lym-
phokine Cytokine Res 13:47–54
120. Dickensheets HL, Freeman SL, Smith MF, Donnelly RP (1997)
Interleukin-10 upregulates tumor necrosis factor receptor type-II
(p75) gene expression in endotoxin-stimulated human mono-
cytes. Blood 90:4162–4171
121. Marfaing-Koka A, Maravic M, Humbert M, Galanaud P, Emilie
D (1996) Contrasting effects of IL-4, IL-10 and corticosteroids
on RANTES production by human monocytes. Int Immunol
8:1587–1594
122. Berkman N, John M, Roesems G, Jose PJ, Barnes PJ, Chung KF
(1995) Inhibition of macrophage inflammatory protein-1 alpha
expression by IL-10. Differential sensitivities in human blood
monocytes and alveolar macrophages. J Immunol 155:4412–4418
Structure and function of interleukin-10 family 2933
123. Asadullah K, Sterry W, Volk HD (2003) Interleukin-10 therapy–
review of a new approach. Pharmacol Rev 55:241–269
124. Levy Y, Brouet JC (1994) Interleukin-10 prevents spontaneous
death of germinal center B cells by induction of the bcl-2 pro-
tein. J Clin Invest 93:424–428
125. Cai G, Kastelein RA, Hunter CA (1999) IL-10 enhances NK cell
proliferation, cytotoxicity and production of IFN-gamma when
combined with IL-18. Eur J Immunol 29:2658–2665
126. Houssiau FA, Lefebvre C, Vanden Berghe M, Lambert M,
Devogelaer JP, Renauld JC (1995) Serum interleukin-10 titers in
systemic lupus erythematosus reflect disease activity. Lupus
4:393–395
127. Lauwerys BR, Garot N, Renauld JC, Houssiau FA (2000)
Interleukin-10 blockade corrects impaired in vitro cellular
immune responses of systemic lupus erythematosus patients.
Arthritis Rheum 43:1976–1981
128. Llorente L, Richaud-Patin Y, Garcia-Padilla C, Claret E, Jakez-
Ocampo J, Cardiel MH, Alcocer-Varela J, Grangeot-Keros L,
Alarcon-Segovia D, Wijdenes J, Galanaud P, Emilie D (2000)
Clinical and biologic effects of anti-interleukin-10 monoclonal
antibody administration in systemic lupus erythematosus.
Arthritis Rheum 43:1790–1800
129. Lubberts E, Joosten LA, Van Den Bersselaar L, Helsen MM,
Bakker AC, Xing Z, Richards CD, Van Den Berg WB (2000)
Intra-articular IL-10 gene transfer regulates the expression of
collagen-induced arthritis (CIA) in the knee and ipsilateral paw.
Clin Exp Immunol 120:375–383
130. Zdanov A, Schalk-Hihi C, Wlodawer A (1996) Crystal structure
of human interleukin-10 at 1.6 A˚ resolution and a model of a
complex with its soluble receptor. Protein Sci 5:1955–1962
131. Ealick SE, Cook WJ, Vijay-Kumar S, Carson M, Nagabhushan
TL, Trotta PP, Bugg CE (1991) Three-dimensional structure of
recombinant human interferon-gamma. Science 252:698–702
132. Randal M, Kossiakoff AA (2000) The 2.0 A˚ structure of bovine
interferon-gamma; assessment of the structural differences
between species. Acta Crystallogr D Biol Crystallogr 56:14–24
133. Samudzi CT, Rubin JR (1993) Structure of recombinant bovine
interferon-gamma at 3.0 A˚ resolution. Acta Crystallogr D Biol
Crystallogr 49:513–521
134. Samudzi CT, Burton LE, Rubin JR (1991) Crystal structure of
recombinant rabbit interferon-gamma at 2.7-A˚ resolution. J Biol
Chem 266:21791–21797
135. Fickenscher H, Biesinger B, Knappe A, Wittmann S, Flecken-
stein B (1996) Regulation of the herpesvirus saimiri oncogene
stpC, similar to that of T-cell activation genes, in growth-
transformed human T lymphocytes. J Virol 70:6012–6019
136. Fickenscher H, Fleckenstein B (2001) Herpesvirus saimiri.
Philos Trans R Soc Lond B Biol Sci 356:545–567
137. Knappe A, Hor S, Wittmann S, Fickenscher H (2000) Induction
of a novel cellular homolog of interleukin-10, AK155, by
transformation of T lymphocytes with herpesvirus saimiri. J
Virol 74:3881–3887
138. Fickenscher H, Pirzer H (2004) Interleukin-26. Int Immuno-
pharmacol 4:609–613
139. Hor S, Pirzer H, Dumoutier L, Bauer F, Wittmann S, Sticht H,
Renauld JC, de Waal Malefyt R, Fickenscher H (2004) The
T-cell lymphokine interleukin-26 targets epithelial cells through
the interleukin-20 receptor 1 and interleukin-10 receptor 2
chains. J Biol Chem 279:33343–33351
140. Sheikh F, Baurin VV, Lewis-Antes A, Shah NK, Smirnov SV,
Anantha S, Dickensheets H, Dumoutier L, Renauld JC, Zdanov
A, Donnelly RP, Kotenko SV (2004) Cutting edge: IL-26 signals
through a novel receptor complex composed of IL-20 receptor 1
and IL-10 receptor 2. J Immunol 172:2006–2010
141. Vandenbroeck K, Cunningham S, Goris A, Alloza I, Heggarty S,
Graham C, Bell A, Rooney M (2003) Polymorphisms in the
interferon-gamma/interleukin-26 gene region contribute to sex
bias in susceptibility to rheumatoid arthritis. Arthritis Rheum
48:2773–2778
142. Dambacher J, Beigel F, Zitzmann K, De Toni EN, Goke B,
Diepolder HM, Auernhammer CJ, Brand S (2009) The role of
the novel Th17 cytokine IL-26 in intestinal inflammation. Gut
58:1207–1217
143. Haque SJ, Sharma P (2006) Interleukins and STAT signaling.
Vitam Horm 74:165–206
144. Seidel HM, Milocco LH, Lamb P, Darnell JE Jr, Stein RB,
Rosen J (1995) Spacing of palindromic half sites as a determi-
nant of selective STAT (signal transducers and activators of
transcription) DNA binding and transcriptional activity. Proc
Natl Acad Sci USA 92:3041–3045
145. Kotenko SV, Langer JA (2004) Full house: 12 receptors for 27
cytokines. Int Immunopharmacol 4:593–608
146. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hart-
mann R (2007) Type III interferon (IFN) induces a type I IFN-
like response in a restricted subset of cells through signaling
pathways involving both the Jak-STAT pathway and the mito-
gen-activated protein kinases. J Virol 81:7749–7758
147. Xu W, Presnell SR, Parrish-Novak J, Kindsvogel W, Jaspers S,
Chen Z, Dillon SR, Gao Z, Gilbert T, Madden K, Schlutsmeyer
S, Yao L, Whitmore TE, Chandrasekher Y, Grant FJ, Maurer M,
Jelinek L, Storey H, Brender T, Hammond A, Topouzis S, Clegg
CH, Foster DC (2001) A soluble class II cytokine receptor,
IL-22RA2, is a naturally occurring IL-22 antagonist. Proc Natl
Acad Sci USA 98:9511–9516
148. Bazan JF (1990) Structural design and molecular evolution of a
cytokine receptor superfamily. Proc Natl Acad Sci USA
87:6934–6938
149. Dumoutier L, de Meester C, Tavernier J, Renauld JC (2009)
New activation modus of STAT3: a tyrosine-less region of the
interleukin-22 receptor recruits STAT3 by interacting with its
coiled-coil domain. J Biol Chem 284:26377–26384
150. de Moura PR, Watanabe L, Bleicher L, Colau D, Dumoutier L,
Lemaire MM, Renauld JC, Polikarpov I (2009) Crystal structure
of a soluble decoy receptor IL-22BP bound to interleukin-22.
FEBS Lett 583:1072–1077
151. Logsdon NJ, Jones BC, Allman JC, Izotova L, Schwartz B,
Pestka S, Walter MR (2004) The IL-10R2 binding hot spot on
IL-22 is located on the N-terminal helix and is dependent on
N-linked glycosylation. J Mol Biol 342:503–514
152. Pletnev S, Magracheva E, Wlodawer A, Zdanov A (2005) A
model of the ternary complex of interleukin-10 with its soluble
receptors. BMC Struct Biol 5:10
153. Yoon SI, Logsdon NJ, Sheikh F, Donnelly RP, Walter MR
(2006) Conformational changes mediate interleukin-10 receptor
2 (IL-10R2) binding to IL-10 and assembly of the signaling
complex. J Biol Chem 281:35088–35096
154. Kotenko SV, Izotova LS, Mirochnitchenko OV, Esterova E,
Dickensheets H, Donnelly RP, Pestka S (2001) Identification,
cloning, and characterization of a novel soluble receptor that
binds IL-22 and neutralizes its activity. J Immunol 166:7096–
7103
155. Dumoutier L, Lejeune D, Colau D, Renauld JC (2001) Cloning
and characterization of IL-22 binding protein, a natural antag-
onist of IL-10-related T cell-derived inducible factor/IL-22.
J Immunol 166:7090–7095
156. Livnah O, Stura EA, Johnson DL, Middleton SA, Mulcahy LS,
Wrighton NC, Dower WJ, Jolliffe LK, Wilson IA (1996)
Functional mimicry of a protein hormone by a peptide agonist:
the EPO receptor complex at 2.8 A˚. Science 273:464–471
157. Kotenko SV, Izotova LS, Mirochnitchenko OV, Esterova E,
Dickensheets H, Donnelly RP, Pestka S (2001) Identification of
the functional interleukin-22 (IL-22) receptor complex: the
2934 D. B. B. Trivella et al.
IL-10R2 chain (IL-10Rbeta) is a common chain of both the
IL-10 and IL-22 (IL-10-related T cell-derived inducible factor,
IL-TIF) receptor complexes. J Biol Chem 276:2725–2732
158. Wu PW, Li J, Kodangattil SR, Luxenberg DP, Bennett F,
Martino M, Collins M, Dunussi-Joannopoulos K, Gill DS,
Wolfman NM, Fouser LA (2008) IL-22R, IL-10R2, and
IL-22BP binding sites are topologically juxtaposed on adjacent
and overlapping surfaces of IL-22. J Mol Biol 382:1168–1183
159. LaPorte SL, Juo ZS, Vaclavikova J, Colf LA, Qi X, Heller NM,
Keegan AD, Garcia KC (2008) Molecular and structural basis of
cytokine receptor pleiotropy in the interleukin-4/13 system. Cell
132:259–272
160. Wolk K, Witte E, Reineke U, Witte K, Friedrich M, Sterry W,
Asadullah K, Volk HD, Sabat R (2005) Is there an interaction
between interleukin-10 and interleukin-22? Genes Immun
6:8–18
161. Preimel D, Sticht H (2004) Molecular modeling of the inter-
leukin-19 receptor complex. Novel aspects of receptor
recognition in the interleukin-10 cytokine family. J Mol Model
10:290–296
162. Walter MR (2004) Structural analysis of IL-10 and Type I
interferon family members and their complexes with receptor.
Adv Protein Chem 68:171–223
163. Thiel DJ, le Du MH, Walter RL, D’Arcy A, Chene C, Founto-
ulakis M, Garotta G, Winkler FK, Ealick SE (2000) Observation
of an unexpected third receptor molecule in the crystal structure
of human interferon-gamma receptor complex. Structure
8:927–936
164. Parrish-Novak J, Foster DC, Holly RD, Clegg CH (2002)
Interleukin-21 and the IL-21 receptor: novel effectors of NK and
T cell responses. J Leukoc Biol 72:856–863
165. Xie MH, Aggarwal S, Ho WH, Foster J, Zhang Z, Stinson J,
Wood WI, Goddard AD, Gurney AL (2000) Interleukin (IL)-22,
a novel human cytokine that signals through the interferon
receptor-related proteins CRF2–4 and IL-22R. J Biol Chem
275:31335–31339
166. Ozaki K, Spolski R, Feng CG, Qi CF, Cheng J, Sher A, Morse
HC 3rd, Liu C, Schwartzberg PL, Leonard WJ (2002) A critical
role for IL-21 in regulating immunoglobulin production. Science
298:1630–1634
167. Doyle WJ, Gentile DA, Cohen S (2006) Emotional style, nasal
cytokines, and illness expression after experimental rhinovirus
exposure. Brain Behav Immun 20:175–181
168. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko
SV, MacDonald MR, Rice CM (2006) Interferons alpha and
lambda inhibit hepatitis C virus replication with distinct signal
transduction and gene regulation kinetics. Gastroenterology
131:1887–1898
169. Waterhouse AM, Procter JB, Martin DM, Clamp M, Barton GJ
(2009) Jalview version 2—a multiple sequence alignment editor
and analysis workbench. Bioinformatics 25:1189–1191
170. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan
PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R,
Thompson JD, Gibson TJ, Higgins DG (2007) ClustalW and
ClustalX version 2.0. Bioinformatics 23:2947–2948
171. DeLano WL (2002) The PyMOL molecular graphics system.
DeLano Scientific, San Carlos
Structure and function of interleukin-10 family 2935
